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ABSTRACT 
 
Deanne Wallander Sammond: Computational redesign of protein-protein 
interactions 
(Under the direction of Dr. Brian Kuhlman) 
 
 
Computational protein modeling predicts and manipulates the biophysical 
properties of proteins based on their amino acid sequences.  Computational 
protein modeling has been applied to protein-protein and protein-peptide 
interactions in order to develop research tools as well as protein therapeutics.  
The intent of our work was to address three areas of protein interface design that 
are of special interest due to their potential applications.  Affinity maturation has 
been used to improve biosensors as well as potential protein therapeutics.  We 
developed a protocol to predict point mutations that will enhance the binding 
affinity of protein-protein interactions.  Extending this work, we evaluated a 
protocol designed to increase protein-peptide binding specificity.  Redesigning 
binding specificity can be used to isolate specific protein interactions within 
complicated signaling networks by limiting the interactions of redesigned proteins 
with their wild type counterparts and other natural binding partners.  Finally, the 
de novo design of a peptide-protein interaction, or the design of a peptide that 
will bind a wild type protein, could enable the creation of biosensors or 
therapeutics from scratch.  We take a step towards this goal by redesigning a 
portion of a peptide backbone in the context of its wild type binding partner.
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CHAPTER I 
INTRODUCTION TO COMPUTATIONAL PROTEIN-PROTEIN INTERFACE 
DESIGN 
 
 2
INTRODUCTION TO COMPUTATIONAL PROTEIN MODELING 
The goal of computational protein modeling is to model the physical laws 
that dictate the form and function of proteins in order to predict or manipulate 
their biophysical properties.  After it was demonstrated that the amino acid 
sequence of a protein determines its structure1; 2 it became the goal of 
computational protein modeling to learn how to model the information in amino 
acid sequences to increase the efficiency of experimental research through the 
power of prediction.  One of the greatest challenges in computational protein 
modeling is to predict the structure of a protein given only the amino acid 
sequence.  The number of known proteins is fast outpacing the number of 
characterized structures.3; 4  The critical assessment of structure prediction, or 
CASP, is a double-blind assessment of the computational algorithms designed to 
predict protein structures.  The CASP experiments have highlighted significant 
progress that has been made in the field protein of structure prediction.5; 6; 7; 8  
Currently, however, high-resolution structure prediction, where the predicted 
structure is within approximately 1.5 angstroms of the x-ray crystal structure,  
seems to be limited to small proteins that are approximately 85 residues or less.9  
A major reason for this limitation seems to be the challenge of sufficiently 
modeling conformational space given current computer limitations.9; 10   
The inverse to computational protein structure prediction is computational 
protein design.  Computational protein design models the same physical laws, 
but starts with protein structures and makes predictions about the amino acid 
sequences that are compatible with those structures.  There are numerous 
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research and industrial applications for protein design, including the creation of 
new enzymes11; 12 and the development of biosensors.13; 14  Many protein design 
applications implement fixed protein backbone design approximations, where the 
backbone torsion angles are those of the experimentally determined structure 
and only the side chains torsion angles are modeled.  Bolon et al. stabilized 
thioredoxin using fixed-backbone protein design to search for sequence positions 
that could accommodate polar amino acids in order to alter the hydrogen bonding 
interactions.15  Desjarlais et al. found that including backbone flexibility when 
modeling protein hydrophobic cores yielded comparable results to fixed-
backbone designs.16  Increasingly complex design challenges appear to require 
some type of backbone modeling.  Joachimiak et al. designed a hydrogen bond 
network by modeling the colicin E6 DNase and Im7 immunity protein complex 
about an axis of rotation.17  Ambroggio et al. designed a protein that can switch 
between two conformations18 and Havrenak et al. engineered coiled-coil binding 
specificity.19  Both of these accomplishments were done by modeling protein 
sequences against an ensemble of protein structures.  The design of the switch 
protein required modeling two different protein backbone structures and 
designing a sequence that is compatible with both structures.  The coiled-coil 
binding specificity was achieved by modeling the homodimer and heterodimer 
interactions and designing a sequence targeted to stabilize the heterodimer 
interaction and then designing a sequence to stabilize the desired interactions 
while destabilizing the undesired interactions.  A new protein fold has been 
designed using a protocol closely related to those used in protein structure 
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prediction,20 blurring the lines between protein structure prediction and protein 
design.   
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COMPUTATIONAL PROTEIN-PROTEIN INTERFACE DESIGN 
Another great challenge in the field of computational protein modeling is 
the prediction and design of protein-protein interactions.  Protein-protein 
interactions form complex cellular networks that regulate most cellular functions.  
Alteration of individual proteins in these complex networks can lead to disease.  
The signaling protein p53 has been implicated in 50% of human cancers,21 
highlighting the need to better understand cellular networks and be able to 
modulate macromolecular complexes.  The three dimensional atomic coordinates 
of a protein give considerable information as to the function of a protein.  There is 
more information needed to thoroughly understand the role of a protein in the 
cell, however, including which other proteins it interacts with.  Experimental 
methods such as yeast two-hybrid assays22 and mass spectrometry23 have been 
used to map out networks of protein-protein interactions.  Computational 
prediction of protein-protein interactions, or computational protein docking, aims 
to increase the efficiency of this work.  As with protein structure prediction, a 
major challenge in computational protein docking is the adequate sampling of 
conformational space.10   
The inverse approach to protein docking prediction is protein-protein 
interface design.  Interface design can benefit from the fact that many proteins do 
not have significant backbone movement upon binding,24 greatly decreasing the 
degrees of freedom that need to be modeled.  This allows many protein-protein 
design protocols to implement fixed-backbone design where the backbone 
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coordinates of the complex are taken from the experimentally determined 
structure and are held fixed.  Cases where a only single sequence position is 
modeled seem to work well with fixed backbone approximation.  Computational 
alanine scanning has been accomplished with fixed-backbone design.25  Our 
work predicting affinity enhancing point mutations indicated that incorporating 
modest backbone flexibility gave comparable results to a much simpler fixed 
backbone protocol.26  Several groups have reengineered the binding specificity of 
calmodulin using the fixed backbone approximation.13; 27; 28  Computational 
protein-protein interface design seeks to look beyond the protein-protein complex 
by providing tools to investigate characteristics of protein-protein interactions 
such as phenotype and cellular location, or to enable us to create protein-protein 
interactions from scratch for the development of protein therapeutics and 
biosensors.  As with monomeric protein design, the protein-protein interface 
design algorithms are increasingly incorporating backbone movement.  This can 
include perturbation of backbone torsion angles, rigid-body docking between two 
protein chains, or the design of entirely new backbone structures.  The most 
impressive specificity redesign results to date incorporated rigid-body backbone 
movement17 where the two protein chains were rotated about each other on an 
axis of rotation.  Huang et al. created a de novo designed protein-protein 
interaction using a docking algorithm.29  Sood et al. enhanced protein-peptide 
binding affinity by designing extensions to peptides at interfaces in order to 
increase the buried surface areas.30  The design of peptide extensions required 
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modeling new backbone coordinates followed by the search for complementary 
sequences. 
 8
   
PREDICTING AFFINITY ENHANCING POINT MUTATIONS 
The work discussed here addresses three fundamental applications of 
protein-protein interface design.  We developed a protocol to predict point 
mutations that will enhance protein-protein or protein-peptide binding affinity.  
This work allowed us to evaluate the predictive power of the Rosetta energy 
function.  We then automated a protocol designed to increase the binding 
specificity of a protein complex.  This protocol was first presented by Kortemme 
et al.31 where they applied it to a protein-protein complex.  We evaluated its use 
with a protein-peptide complex.  Lastly we develop a protocol to design a new 
backbone and sequence of a peptide in the context of one a wild type binding 
partner.  This protocol borrows from methods used for protein structure 
prediction32 by building a peptide backbone from fragments taken from existing 
structures in the protein data bank33 followed by iterations of sequence design.34        
First, we developed a protocol for the prediction of point mutations that will 
enhance protein-protein binding affinity.  Protein-protein binding affinity has 
practical applications for both research and protein therapeutics.  Antibodies 
used in immunoassays can have improved performance with enhanced binding 
affinity,35 or antibodies specific for predetermined targets that are isolated from 
libraries often require affinity maturation in order to achieve the desired 
therapeutic results.36  One approach to enhance protein-protein binding affinity is 
to increase the electrostatic interactions between two proteins.  This is typically 
done by modeling the residues on the periphery of the interface.  This approach 
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has been successfully used to increase the affinity between TEM1 β-lactamase 
and its protein inhibitor BLIP by over 250-fold,37 and the affinity between Ral and 
Ral guanine nucleotide dissociation stimulator by over 25-fold.38  This approach 
works best when there are large like-charged regions on a protein chain that are 
not paired with the charges on the other side of the interface.  An alternative 
approach is to model the residues that are buried at the protein-protein interface 
to improve hydrophobic packing, hydrogen bonding or desolvation energies.  The 
basis for our protocol is that increasing buried hydrophobic surface area across 
the interface can stabilize the protein-protein interaction provided destabilizing 
effects such as steric clashes, unsatisfied hydrogen bonds or destabilization of 
individual protein chains does not occur.  Mutational studies of buried 
hydrophobic residues highlight the importance of a tightly packed core in the 
stability of monomeric proteins.39; 40  We apply these finding to protein-protein 
interactions, using the protein design software, RosettaDesign, to model point 
mutations at the interface and predict the resulting ∆∆Gbinding.   
 10
 
REDESIGNING PROTEIN-PEPTIDE BINDING SPECIFICITY 
The second goal we address deals with the rational manipulation of 
protein-peptide binding specificity.  Computational redesigns of protein-protein 
binding specificity have used positive protein design, where protein sequences 
are designed to stabilize the desired interaction, and combinations of positive 
and negative design.  Negative protein design designs a sequence to destabilize 
undesired interactions.  Protein-protein binding specificity for calmodulin was 
successfully reengineered using positive protein design by redesigning the 
interface of the desired interaction only.27  Both positive and negative protein 
design were used to design binding specificity of a coiled-coil interaction using 
positive and negative design simultaneously.  Sequence positions were deigned 
based on an amino acid’s ability to stabilize the desired interaction while 
destabilize the undesired interactions.19  Our protocol searched for point 
mutations at a protein-peptide interface that would disrupt the wild-type 
interaction.  Sequence positions that neighbor the destabilizing mutation were 
then redesigned in an effort to regain wild-type binding affinity.  The goal was for 
the resulting redesigned protein complex to bind as the wild-type complex does 
but not to cross-interact with its wild-type counterparts.  The idea was that not 
only will the redesigned proteins not interact with their wild type counterparts, but 
that this specificity will extend to the homologous family members of the wild type 
counterparts.  In this way the redesigned protein-protein interaction could be 
isolated from the complex cellular network in which it participates.  This type of 
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redesigned specificity could allow for the rewiring of cellular networks as well as 
the creation of biosensors that could be used for live in cell imaging.  This 
automated computational protocol is based on the work by Kortemme et al., 
where they introduced this protocol to redesign the specificity of the colicin E6 
DNase-Im7 immunity protein complex.31  Here we automated the protocol and 
applied it to a protein-peptide complex.    
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de novo PROTEIN-PEPTIDE INTERFACE DESIGN 
Our final aim was to develop a protocol that can design a peptide 
backbone and sequence that will bind a wild type protein. This project was a 
small step toward a full de novo protein-protein interface design.  Modeling 
backbone flexibility is currently seen as one of the major challenges in 
computational protein design mainly because of the increase in degrees of 
freedom that need to be sampled.10; 41  Ultimately the goals of protein design 
depend on algorithms that can balance computational limitations with need to 
more extensively sample sequence and structure space.  Our final aim 
addressed the area of backbone design at protein-protein interfaces.  We began 
with an x-ray crystal structure of a protein-peptide interface; we removed a 
portion of one binding partner and redesigned the backbone of that region to 
have an entirely different secondary structure and sequence within the context of 
the wild-type binding partner.     
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ROSETTA PROTEIN DESIGN SOFTWARE 
We used the computational prediction and design program, Rosetta, to 
redesign protein-peptide interactions.32  Rosetta was created for protein structure 
prediction.9  Rosetta has had tremendous success in the critical assessment of 
structure prediction experiments (CASP)6; 8 and was subsequently applied to 
protein docking prediction10; 42 and protein design.34  Rosetta has been used to 
alter the folding path of a protein,43 refine experimentally determined protein 
structures44 and design a novel protein fold.20 Rosetta uses a Monte Carlo 
simulated annealing search procedure by making random perturbations to 
backbone or side chain torsion angles. The Monte Carlo algorithm is used for 
both side-chain design as well as backbone movement.  The search algorithm is 
directed by an all-atom energy function that focuses on short-range interactions.  
We used the all-atom mode of Rosetta to model the amino acids when designing 
protein sequences or predicting the free energy of binding and the stability of 
monomeric proteins.  The energy function is comprised of a linear sum of 
molecular mechanics and knowledge-based terms.  These include a Lennard-
Jones potential, a distance and orientation dependent hydrogen bonding 
potential,45 and the Lazaridis-Karplus implicit solvation model.46  We primarily use 
a version of the energy function that was parameterized to best reproduce native 
sequences when redesigning whole proteins in fixed backbone simulations 
(command line option, -soft_rep_design , Rosetta v 2.1).  This variation of the 
energy function significantly dampens repulsion energies to allow for small atom-
atom clashes that may be accommodated by small changes in side chain and 
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backbone conformation.  See supplementary material of Dantas et al. for a 
complete description of this version of the Rosetta energy function.  It is referred 
to as Rosetta_DampRep.47  We use this dampened repulsion model for most of 
the work presented here, including designs where the backbone torsion angles 
are fixed as well as design runs that include movement of the backbone.  There 
is a reference energy that is meant to represent the energy of the amino acids in 
an unfolded state.34  Amino acid side-chains are represented in discrete 
conformations taken from a rotamer library.48  We expand the Dunbrack rotamer 
library by varying the chi 1 and chi 2 angles one standard deviation away from 
their most probable values in an effort to prevent the overestimation of 
destabilizing effects that can result from modeling with discrete side chain 
conformations on a fixed backbone scaffold.  The backbone phi and psi angles 
are evaluated using Ramachandran torsion preferences.49  In addition to 
Rosetta’s atomic-level potential function we use a more course-grained, centroid-
based energy function where amino acid side chains are represented by 
centroids located at the side-chain center of mass.  The centroid mode is used 
when significant backbone modeling is performed.  The centroid mode runs are 
followed by all-atom designs in order to obtain the high-resolution structures and 
energetic predictions needed for protein-peptide interface design.  We also 
evaluate gradient based minimization of side chain and backbone torsion angles 
and rigid body docking using a quasi-Newton method.32   This allows small side 
chain and backbone movements intended to relieve slight van der Waals 
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overlaps between amino acids as well as provide a way to improve hydrogen 
bond angles and distances.   
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MODEL SYSTEMS USED FOR EXPERIMENTAL VALIDATION 
The model system that we use for the experimental validation of our 
computational protocols is the Gαi1 protein from the heterotrimeric G-protein 
system bound to the GoLoco motif from the RGS14 multidomain regulatory 
protein.50  Heterotrimeric Gα proteins have intrinsic GTPase activity, enabling 
them to switch from their active, guanosine triphosphate (GTP)-bound 
conformation to their inactive, guanosine diphosphate (GDP)-bound conformation 
by hydrolyzing the γ phosphate of the GTP.  The GoLoco motif has been shown 
to selectively bind the GDP-bound Gα proteins from the adenylyl-cyclase-
inhibitory subclass.51  Upon binding, the GoLoco motif stabilizes the bound 
nucleotide in the Gα protein, thereby acting as a guanine nucleotide dissociation 
inhibitor (GDI).52; 53; 54  The ability for the GoLoco motifs to bind the inactive, 
GDP-bound Gα proteins in place of the Gβγ heterodimer suggests a role for the 
GoLoco in G protein-coupled receptor signaling.  Experimental evidence 
suggests, however, that the GoLoco motifs are involved in spindle-pole 
organization, chromosomal segregation, and asymmetric cell division.55; 56  The 
exact biochemical roles of the GoLoco motifs is not currently understood.  
Questions remain as to the role the GoLoco motifs and the GoLoco-Gα i/o 
complexes might play in these processes, as well as the methods of regulation 
involved.55  Rationally redesigned GoLoco-Gα complexes could provide novel 
investigative tools.  A redesigned RGS14 GoLoco motif that binds a redesigned 
Gαi1 protein, exhibiting biophysical behavior similar to that of the wild-type 
complex, could be used to investigate whether the RGS14 GoLoco-Gαi1 complex 
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and the RGS14 GoLoco-Gαi3 complex have distinguishable roles.  GoLoco motifs 
with enhanced binding specificity could also be used as biosensors with 
improved signal to noise ratios.   
In addition to a biochemical interest, the RGS14 GoLoco-Gαi1 complex 
was selected because the interface has a number of structural features that 
make it a good target for computational protein design.  The 36-residue GoLoco 
motif of RGS14 binds to the GDP-bound state of the Gαi1 protein and interacts 
with both the Ras-like, guanine nucleotide binding domain and the all-helical 
domain of the Gαi1 protein.50  The Gαi1–RGS14 GoLoco interface buries over 
1900 Å2 of surface area and has a low nanomolar binding affinity.26; 50  We can 
investigate how our protocols work on the more flexible Ras-like Gαi1 domain, 
which includes a flexible region termed switch II, which has been shown to 
undergo conformational change upon nucleotide exchange or hydrolysis.   The 
all-helical domain of the Gαi1 protein provides a less flexible domain which 
appears to undergo only a very slight backbone movement in helix αB as seen 
when comparing one of the unbound Gαi1 structures (PDB ID: 1GIA)57 with the 
GoLoco complex.50   
Our development of a protocol to predict affinity enhancing point mutations 
is experimentally and computationally accessible enough that we were able to 
include a second protein model system for additional proof of principle.  The 
second protein model system for our affinity enhancing protocol is the E2, 
ubiquitin-conjugating enzyme UbcH7, bound to the E3, E6-associated protein 
(E6AP), from the ubiquitin pathway.58   This UbcH7-E6AP complex differs from 
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the GoLoco-Gαi1 complex in that the individual protein components undergo little 
conformational change upon binding.  The structures of E6AP in the unbound 
state is virtually identical to the conformation that it adopts when forming a 
complex.58  Likewise the UbcH7 fold observed in the UbcH7-E6AP complex is 
similar to that of numerous unbound structures of other ubiquitin conjugating 
enzymes.59    
 19
 
REFERENCES 
1. Anfinsen, C. B. (1973). Principles that govern the folding of protein chains. 
Science 181, 223-30. 
 
2. Anfinsen, C. B., Haber, E., Sela, M. & White, F. H., Jr. (1961). The kinetics 
of formation of native ribonuclease during oxidation of the reduced 
polypeptide chain. Proc Natl Acad Sci U S A 47, 1309-14. 
 
3. Rost, B. (1998). Marrying structure and genomics. Structure 6, 259-63. 
 
4. Berman, H. M., Bhat, T. N., Bourne, P. E., Feng, Z., Gilliland, G., Weissig, 
H. & Westbrook, J. (2000). The Protein Data Bank and the challenge of 
structural genomics. Nat Struct Biol 7 Suppl, 957-9. 
 
5. Bonneau, R., Tsai, J., Ruczinski, I., Chivian, D., Rohl, C., Strauss, C. E. & 
Baker, D. (2001). Rosetta in CASP4: progress in ab initio protein structure 
prediction. Proteins Suppl 5, 119-26. 
 
6. Bradley, P., Chivian, D., Meiler, J., Misura, K. M., Rohl, C. A., Schief, W. 
R., Wedemeyer, W. J., Schueler-Furman, O., Murphy, P., Schonbrun, J., 
Strauss, C. E. & Baker, D. (2003). Rosetta predictions in CASP5: 
successes, failures, and prospects for complete automation. Proteins 53 
Suppl 6, 457-68. 
 
7. Kryshtafovych, A., Venclovas, C., Fidelis, K. & Moult, J. (2005). Progress 
over the first decade of CASP experiments. Proteins 61 Suppl 7, 225-36. 
 
8. Lesk, A. M., Lo Conte, L. & Hubbard, T. J. (2001). Assessment of novel 
fold targets in CASP4: predictions of three-dimensional structures, 
secondary structures, and interresidue contacts. Proteins Suppl 5, 98-
118. 
 
9. Bradley, P., Misura, K. M. & Baker, D. (2005). Toward high-resolution de 
novo structure prediction for small proteins. Science 309, 1868-71. 
 
10. Schueler-Furman, O., Wang, C., Bradley, P., Misura, K. & Baker, D. 
(2005). Progress in modeling of protein structures and interactions. 
Science 310, 638-42. 
 
11. Jiang, L., Althoff, E. A., Clemente, F. R., Doyle, L., Rothlisberger, D., 
Zanghellini, A., Gallaher, J. L., Betker, J. L., Tanaka, F., Barbas, C. F., 
3rd, Hilvert, D., Houk, K. N., Stoddard, B. L. & Baker, D. (2008). De novo 
computational design of retro-aldol enzymes. Science 319, 1387-91. 
 20
 
12. Rothlisberger, D., Khersonsky, O., Wollacott, A. M., Jiang, L., DeChancie, 
J., Betker, J., Gallaher, J. L., Althoff, E. A., Zanghellini, A., Dym, O., 
Albeck, S., Houk, K. N., Tawfik, D. S. & Baker, D. (2008). Kemp 
elimination catalysts by computational enzyme design. Nature 453, 190-5. 
 
13. Palmer, A. E., Giacomello, M., Kortemme, T., Hires, S. A., Lev-Ram, V., 
Baker, D. & Tsien, R. Y. (2006). Ca2+ indicators based on computationally 
redesigned calmodulin-peptide pairs. Chem Biol 13, 521-30. 
 
14. de Lorimier, R. M., Smith, J. J., Dwyer, M. A., Looger, L. L., Sali, K. M., 
Paavola, C. D., Rizk, S. S., Sadigov, S., Conrad, D. W., Loew, L. & 
Hellinga, H. W. (2002). Construction of a fluorescent biosensor family. 
Protein Sci 11, 2655-75. 
 
15. Bolon, D. N., Marcus, J. S., Ross, S. A. & Mayo, S. L. (2003). Prudent 
modeling of core polar residues in computational protein design. J Mol Biol 
329, 611-22. 
 
16. Desjarlais, J. R. & Handel, T. M. (1999). Side-chain and backbone 
flexibility in protein core design. J Mol Biol 290, 305-18. 
 
17. Joachimiak, L. A., Kortemme, T., Stoddard, B. L. & Baker, D. (2006). 
Computational design of a new hydrogen bond network and at least a 
300-fold specificity switch at a protein-protein interface. J Mol Biol 361, 
195-208. 
 
18. Ambroggio, X. I. & Kuhlman, B. (2006). Computational design of a single 
amino acid sequence that can switch between two distinct protein folds. J 
Am Chem Soc 128, 1154-61. 
 
19. Havranek, J. J. & Harbury, P. B. (2003). Automated design of specificity in 
molecular recognition. Nat Struct Biol 10, 45-52. 
 
20. Kuhlman, B., Dantas, G., Ireton, G. C., Varani, G., Stoddard, B. L. & 
Baker, D. (2003). Design of a novel globular protein fold with atomic-level 
accuracy. Science 302, 1364-8. 
 
21. Gasco, M., Shami, S. & Crook, T. (2002). The p53 pathway in breast 
cancer. Breast Cancer Res 4, 70-6. 
 
22. Uetz, P., Giot, L., Cagney, G., Mansfield, T. A., Judson, R. S., Knight, J. 
R., Lockshon, D., Narayan, V., Srinivasan, M., Pochart, P., Qureshi-Emili, 
A., Li, Y., Godwin, B., Conover, D., Kalbfleisch, T., Vijayadamodar, G., 
Yang, M., Johnston, M., Fields, S. & Rothberg, J. M. (2000). A 
 21
comprehensive analysis of protein-protein interactions in Saccharomyces 
cerevisiae. Nature 403, 623-7. 
 
23. Gavin, A. C., Bosche, M., Krause, R., Grandi, P., Marzioch, M., Bauer, A., 
Schultz, J., Rick, J. M., Michon, A. M., Cruciat, C. M., Remor, M., Hofert, 
C., Schelder, M., Brajenovic, M., Ruffner, H., Merino, A., Klein, K., Hudak, 
M., Dickson, D., Rudi, T., Gnau, V., Bauch, A., Bastuck, S., Huhse, B., 
Leutwein, C., Heurtier, M. A., Copley, R. R., Edelmann, A., Querfurth, E., 
Rybin, V., Drewes, G., Raida, M., Bouwmeester, T., Bork, P., Seraphin, 
B., Kuster, B., Neubauer, G. & Superti-Furga, G. (2002). Functional 
organization of the yeast proteome by systematic analysis of protein 
complexes. Nature 415, 141-7. 
 
24. Betts, M. J. & Sternberg, M. J. (1999). An analysis of conformational 
changes on protein-protein association: implications for predictive docking. 
Protein Eng 12, 271-83. 
 
25. Kortemme, T., Kim, D. E. & Baker, D. (2004). Computational alanine 
scanning of protein-protein interfaces. Sci STKE 2004, pl2. 
 
26. Sammond, D. W., Eletr, Z. M., Purbeck, C., Kimple, R. J., Siderovski, D. 
P. & Kuhlman, B. (2007). Structure-based protocol for identifying 
mutations that enhance protein-protein binding affinities. J Mol Biol 371, 
1392-404. 
 
27. Shifman, J. M. & Mayo, S. L. (2002). Modulating calmodulin binding 
specificity through computational protein design. J Mol Biol 323, 417-23. 
 
28. Green, D. F., Dennis, A. T., Fam, P. S., Tidor, B. & Jasanoff, A. (2006). 
Rational design of new binding specificity by simultaneous mutagenesis of 
calmodulin and a target peptide. Biochemistry 45, 12547-59. 
 
29. Huang, P. S., Love, J. J. & Mayo, S. L. (2007). A de novo designed protein 
protein interface. Protein Sci 16, 2770-4. 
 
30. Sood, V. D. & Baker, D. (2006). Recapitulation and design of protein 
binding peptide structures and sequences. J Mol Biol 357, 917-27. 
 
31. Kortemme, T., Joachimiak, L. A., Bullock, A. N., Schuler, A. D., Stoddard, 
B. L. & Baker, D. (2004). Computational redesign of protein-protein 
interaction specificity. Nat Struct Mol Biol 11, 371-9. 
 
32. Rohl, C. A., Strauss, C. E., Misura, K. M. & Baker, D. (2004). Protein 
structure prediction using Rosetta. Methods Enzymol 383, 66-93. 
 
 22
33. Berman, H. M., Battistuz, T., Bhat, T. N., Bluhm, W. F., Bourne, P. E., 
Burkhardt, K., Feng, Z., Gilliland, G. L., Iype, L., Jain, S., Fagan, P., 
Marvin, J., Padilla, D., Ravichandran, V., Schneider, B., Thanki, N., 
Weissig, H., Westbrook, J. D. & Zardecki, C. (2002). The Protein Data 
Bank. Acta Crystallogr D Biol Crystallogr 58, 899-907. 
 
34. Kuhlman, B. & Baker, D. (2000). Native protein sequences are close to 
optimal for their structures. Proc Natl Acad Sci U S A 97, 10383-8. 
 
35. Siegel, R. W., Baugher, W., Rahn, T., Drengler, S. & Tyner, J. (2008). 
Affinity Maturation of Tacrolimus Antibody for Improved Immunoassay 
Performance. Clin Chem. 
 
36. Sheedy, C., MacKenzie, C. R. & Hall, J. C. (2007). Isolation and affinity 
maturation of hapten-specific antibodies. Biotechnol Adv 25, 333-52. 
 
37. Selzer, T., Albeck, S. & Schreiber, G. (2000). Rational design of faster 
associating and tighter binding protein complexes. Nat Struct Biol 7, 537-
41. 
 
38. Kiel, C., Selzer, T., Shaul, Y., Schreiber, G. & Herrmann, C. (2004). 
Electrostatically optimized Ras-binding Ral guanine dissociation stimulator 
mutants increase the rate of association by stabilizing the encounter 
complex. Proc Natl Acad Sci U S A 101, 9223-8. 
 
39. Bowie, J. U., Reidhaar-Olson, J. F., Lim, W. A. & Sauer, R. T. (1990). 
Deciphering the message in protein sequences: tolerance to amino acid 
substitutions. Science 247, 1306-10. 
 
40. Matthews, B. W. (1995). Studies on protein stability with T4 lysozyme. Adv 
Protein Chem 46, 249-78. 
 
41. Kortemme, T. & Baker, D. (2004). Computational design of protein-protein 
interactions. Curr Opin Chem Biol 8, 91-7. 
 
42. Gray, J. J., Moughon, S. E., Kortemme, T., Schueler-Furman, O., Misura, 
K. M., Morozov, A. V. & Baker, D. (2003). Protein-protein docking 
predictions for the CAPRI experiment. Proteins 52, 118-22. 
 
43. Nauli, S., Kuhlman, B. & Baker, D. (2001). Computer-based redesign of a 
protein folding pathway. Nat Struct Biol 8, 602-5. 
 
44. Qian, B., Raman, S., Das, R., Bradley, P., McCoy, A. J., Read, R. J. & 
Baker, D. (2007). High-resolution structure prediction and the 
crystallographic phase problem. Nature 450, 259-64. 
 
 23
45. Kortemme, T., Morozov, A. V. & Baker, D. (2003). An orientation-
dependent hydrogen bonding potential improves prediction of specificity 
and structure for proteins and protein-protein complexes. J Mol Biol 326, 
1239-59. 
 
46. Lazaridis, T. & Karplus, M. (1999). Effective energy function for proteins in 
solution. Proteins 35, 133-52. 
 
47. Dantas, G., Corrent, C., Reichow, S. L., Havranek, J. J., Eletr, Z. M., Isern, 
N. G., Kuhlman, B., Varani, G., Merritt, E. A. & Baker, D. (2006). High-
resolution Structural and Thermodynamic Analysis of Extreme 
Stabilization of Human Procarboxypeptidase by Computational Protein 
Design. J Mol Biol. 
 
48. Dunbrack, R. L., Jr. & Cohen, F. E. (1997). Bayesian statistical analysis of 
protein side-chain rotamer preferences. Protein Sci 6, 1661-81. 
 
49. Bowers, P. M., Strauss, C. E. & Baker, D. (2000). De novo protein 
structure determination using sparse NMR data. J Biomol NMR 18, 311-8. 
 
50. Kimple, R. J., Kimple, M. E., Betts, L., Sondek, J. & Siderovski, D. P. 
(2002). Structural determinants for GoLoco-induced inhibition of 
nucleotide release by Galpha subunits. Nature 416, 878-81. 
 
51. Siderovski, D. P., Diverse-Pierluissi, M. & De Vries, L. (1999). The 
GoLoco motif: a Galphai/o binding motif and potential guanine-nucleotide 
exchange factor. Trends Biochem Sci 24, 340-1. 
 
52. De Vries, L., Fischer, T., Tronchere, H., Brothers, G. M., Strockbine, B., 
Siderovski, D. P. & Farquhar, M. G. (2000). Activator of G protein 
signaling 3 is a guanine dissociation inhibitor for Galpha i subunits. Proc 
Natl Acad Sci U S A 97, 14364-9. 
 
53. Peterson, Y. K., Bernard, M. L., Ma, H., Hazard, S., 3rd, Graber, S. G. & 
Lanier, S. M. (2000). Stabilization of the GDP-bound conformation of 
Gialpha by a peptide derived from the G-protein regulatory motif of AGS3. 
J Biol Chem 275, 33193-6. 
 
54. Natochin, M., Gasimov, K. G. & Artemyev, N. O. (2001). Inhibition of 
GDP/GTP exchange on G alpha subunits by proteins containing G-protein 
regulatory motifs. Biochemistry 40, 5322-8. 
 
55. Willard, F. S., Kimple, R. J. & Siderovski, D. P. (2004). Return of the GDI: 
the GoLoco motif in cell division. Annu Rev Biochem 73, 925-51. 
 
 24
56. Kimple, R. J., Willard, F. S. & Siderovski, D. P. (2002). The GoLoco motif: 
heralding a new tango between G protein signaling and cell division. Mol 
Interv 2, 88-100. 
 
57. Coleman, D. E., Berghuis, A. M., Lee, E., Linder, M. E., Gilman, A. G. & 
Sprang, S. R. (1994). Structures of active conformations of Gi alpha 1 and 
the mechanism of GTP hydrolysis. Science 265, 1405-12. 
 
58. Huang, L., Kinnucan, E., Wang, G., Beaudenon, S., Howley, P. M., 
Huibregtse, J. M. & Pavletich, N. P. (1999). Structure of an E6AP-UbcH7 
complex: insights into ubiquitination by the E2-E3 enzyme cascade. 
Science 286, 1321-6. 
 
59. Pickart, C. M. (2001). Mechanisms underlying ubiquitination. Annu Rev 
Biochem 70, 503-33. 
 
 
 
  
 
 
 
 
 
CHAPTER II 
 
STRUCTURE-BASED PROTOCOL FOR IDENTIFYING 
MUTATIONS THAT ENHANCE PROTEIN-PROTEIN BINDING 
AFFINITIES 
 
Deanne W Sammond1, Ziad M Eletr1, Carrie Purbeck1, Randall J 
Kimple2, David P Siderovski2, & Brian Kuhlman1* 
1Department of Biochemistry and Biophysics, University of North 
Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7260, USA 
2Department of Pharmacology, University of North Carolina at Chapel 
Hill, Chapel Hill, North Carolina 27599-7365, USA 
*Corresponding Author 
 
 
This work was published in the Journal of Molecular Biology (2007) 
371(5):1392-1404. 
 
Reproduced with permission from Elsevier B.V.
 26
ABSTRACT 
The ability to manipulate protein binding affinities is important for the 
development of proteins as biosensors, industrial reagents, and therapeutics. We 
have developed a structure-based method to rationally predict single mutations 
at protein–protein interfaces that enhance binding affinities. The method is based 
on the premise that increasing buried hydrophobic surface area and/or reducing 
buried hydrophilic surface area will generally lead to enhanced affinity if large 
steric clashes are not introduced and buried polar groups are not left without a 
hydrogen bond partner. The procedure selects affinity enhancing point mutations 
at the protein–protein interface using three criteria: (1) the mutation must be from 
a polar amino acid to a non-polar amino acid or from a non-polar amino acid to a 
larger non-polar amino acid, (2) the free energy of binding as calculated with the 
Rosetta protein modeling program should be more favorable than the free energy 
of binding calculated for the wild-type complex and (3) the mutation should not be 
predicted to significantly destabilize the monomers. The performance of the 
computational protocol was experimentally tested on two separate protein 
complexes; Gαi1 from the heterotrimeric G-protein system bound to the RGS14 
GoLoco motif, and the E2, UbcH7, bound to the E3, E6AP from the ubiquitin 
pathway. Twelve single-site mutations that were predicted to be stabilizing were 
synthesized and characterized in the laboratory. Nine of the 12 mutations 
successfully increased binding affinity with five of these increasing binding by 
over 1.0 kcal/mol. To further assess our approach we searched the literature for 
point mutations that pass our criteria and have experimentally determined 
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binding affinities. Of the eight mutations identified, five were accurately predicted 
to increase binding affinity, further validating the method as a useful tool to 
increase protein–protein binding affinities. 
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INTRODUCTION 
Engineered proteins are increasingly being used as therapeutics and as 
tools to probe cell biology.1; 2; 3  Often, the effectiveness of these proteins 
depends in part on their affinity for their target ligand or protein. Directed 
evolution and combinatorial screening techniques such as phage display or 
ribosome display are successful and well accepted means of engineering protein 
complexes with enhanced affinity.4; 5  These techniques, however, are labor 
intensive and are difficult to perform in cases where the target protein is difficult 
to express or is not stable under the conditions needed for binding selection. An 
alternative approach is to use structure-based modeling to predict affinity-
increasing mutations. The limitation of this approach is that it requires a high 
resolution structure of the protein–protein interface that is being optimized. 
Benefits are that it has the potential to be a rapid way to identify stabilizing 
mutations and it can be used in cases where combinatorial screening is not 
feasible.  
In general, two types of structure-based approaches have been used to 
enhance protein–protein binding affinities. One approach has focused on 
increasing the electrostatic attraction between proteins by mutating residues 
around the periphery of the binding interface.6; 7; 8; 9  The rationale is that 
electrostatic interactions can work over long distances and therefore the 
additional charges do not need to be immediately adjacent to the partner protein. 
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The benefit of restricting mutations to the periphery is that the specific packing 
and hydrogen bonding that is often found at interfaces is not disrupted. This 
approach has been used with good success. Mutations have been identified that 
increase the affinity between TEM1 β-lactamase and its protein inhibitor BLIP by 
over 250-fold,8 and the affinity between Ral and Ral guanine nucleotide 
dissociation stimulator by over 25-fold.9  One limitation of this approach is that 
large increases in binding affinity are only possible in cases where there is an 
excess of like-charge on one side of the interface that is not already paired with 
the opposite charge on the other side of the interface. 
An alternative approach is to use side-chain repacking algorithms to 
search for mutations that lead to better packing, hydrogen bonding, and 
desolvation energies at the interface. These protocols generally model protein 
energetics with a linear combination of terms that model van der Waals forces, 
steric repulsion, backbone and side-chain torsional energies, hydrogen bonding, 
desolvation energies and electrostatics. Often the protein backbone is held rigid 
and side-chains are restricted to the most commonly observed conformations in 
the Protein Data Bank (PDB), typically referred to as rotamers. This technology, 
often referred to as computational protein design, has been used to design new 
protein structures,10 create new enzymes,11; 12; 13 stabilize proteins14; 15; 16; 17; 18 
and perturb protein–protein binding specificities.19; 20; 21; 22; 23  Recently, two 
studies made extensive use of a variety of protein design algorithms in an effort 
to enhance protein–protein binding affinities. Springer and colleagues used 
Protein Design Automation (PDA), Sequence Prediction Algorithm, and Rosetta 
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to search for mutations that would stabilize the interaction between integrin 
lymphocyte function-associated antigen-1 (LFA-1) and its ligand intercellular 
adhesion molecule-1 (ICAM-1).24  Mixed results were obtained with the 
algorithms. Out of 24 single and double mutations that were selected for 
experimental characterization, four of the redesigns increased binding by over 
1.5-fold. In a separate study, Clark and co-workers used a side-chain repacking 
algorithm to search for mutations that would increase the affinity of an antibody 
for its protein target.25  Most of the point mutations studied did not significantly 
increase binding affinity, but by combining three mutations they were able to 
stabilize binding by 1.2 kcal/mol. Interestingly, in the Springer study three out of 
the four stabilizing mutations were from a polar amino acid to a non-polar amino 
acid, and in the Clark study two out of the three stabilizing mutations changed a 
polar amino acid to a non-polar amino acid. Although this is a small test set, this 
result suggests that side-chain repacking algorithms may be most successful at 
enhancing protein–protein binding affinities when limited to mutations that 
decrease the amount of buried hydrophilic groups and increase the number of 
buried hydrophobic groups. 
The hydrophobic effect drives protein folding, and hydrophobic 
interactions often contribute significantly to protein–protein binding affinity. 
Removing a buried methylene or methyl group by site-directed mutagenesis 
almost always destabilizes a protein, often by more than 1 kcal/mol.26; 27  
Introducing new methylene groups can stabilize a protein, and side-chain 
repacking algorithms have been used to stabilize proteins by identifying residues 
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within a protein core that can accommodate larger hydrophobic amino acids.15; 16; 
17; 28  Burying hydrophilic groups has the opposite effect on protein stability. 
There is a large desolvation cost associated with placing a polar amino acid in 
the interior of a protein, to the point where buried polar groups are only found in 
positions where they can form hydrogen bonds with other polar groups in the 
protein. The balance between hydrogen bond energy and desolvation energy 
plays a large part in determining the favorability of a buried polar amino acid.28; 29; 
30  Accurately calculating this balance is difficult, in part because the calculation 
is sensitive to small structural perturbations given that hydrogen bonds have a 
sharp distance and orientation dependence.30; 31 In addition, cooperative effects 
in hydrogen bond networks may change the average hydrogen bond energy 
within the network.32 
Here, we test our ability to predict point mutations that will enhance 
protein–protein binding affinities. Because accurately calculating the favorability 
of a buried polar amino acid is difficult, we focus on mutations that do not rely on 
hydrogen bonding to overcome desolvation energies. We consider two types of 
mutations at protein interfaces: mutation from a hydrophobic amino acid to a 
larger hydrophobic amino acid, and mutation of partially buried polar groups, not 
involved in side-chain hydrogen bonding, to a non-polar amino acid. We model 
the mutations and calculate binding energies using Rosetta, protein modeling 
software that has been developed for protein structure prediction and design.33  
We use two separate model protein systems to experimentally validate our 
protocol; from the G protein system we use the Gαi1 protein with one of its 
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binding partners, the GoLoco motif from the Gα regulator, RGS14,34 and from the 
ubiquitin pathway, we use the ubiquitin-conjugating enzyme UbcH7 along with 
one of its binding partners, E6-associated protein (E6AP) (Figure 2.1).35  We 
chose these interfaces as model systems because they are large (>2000 Å2), 
which increases the probability of finding point mutations that meet our selection 
criteria. Additionally, these systems allow us to test our protocol on both a 
protein–peptide (Gαi1–GoLoco) and a protein–protein interaction (UbcH7–E6AP). 
We do not explicitly model backbone conformational change in the unbound 
state, and therefore, our modeling procedure does not differentiate between a 
flexible peptide and a rigid protein. If mutations dramatically affect the unbound 
conformation of the GoLoco peptide, we may observe less accurate predictions 
for the GoLoco–Gαi1 interface. 
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RESULTS 
For both model systems, Gαi1-GoLoco and UbcH7-E6AP, each residue at 
the protein–protein interface was sequentially mutated to the non-polar amino 
acids (V,I,L,M,F,Y,W) and changes to binding energy were predicted with the 
Rosetta energy function. In cases where a non-polar amino acid was being 
mutated to another non-polar, only mutations that increased the size of the side-
chain were considered. Binding energies were calculated by subtracting the 
calculated energy of each unbound protein from the calculated energy of the 
complex. In the first round of calculations, the backbone and side-chain 
conformations of the unbound proteins were assumed to be identical to those in 
the bound state. The side-chain of the mutated residue was built by choosing the 
rotamer with the lowest energy when modeled in the context of the complex. 
Neighboring side-chains were held fixed in the positions observed in the crystal 
structure. 
Predicting affinity-enhancing mutations at the GoLoco–Gαi1 
interface 
The 36-residue GoLoco motif peptide of RGS14 stretches across the Gαi1 
surface, interacting with both the Ras-like, guanine nucleotide binding domain 
and the all-helical domain of Gαi1.34  A total of 28 residues from the GoLoco motif 
and 59 residues from Gαi1 interact at the protein–peptide interface. Each 
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interface position was sequentially mutated to a non-polar amino acid and the 
binding energies were calculated. From the 503 mutations that were considered, 
55 have calculated binding energies that are more favorable by 0.5 kcal/mol or 
more than the wild-type protein. However, many of these mutations are predicted 
to create unfavorable intramolecular interactions (∆∆G°chain in Table 2.1), which 
will indirectly weaken binding by disfavoring the backbone and side-chain 
conformations adopted in the bound state. For example, residue 203 in wild-type 
Gαi1 is a glycine with a phi angle in a region of the Ramachandran plot that is 
disfavored for most amino acids. Because we are assuming that the 
conformation of the unbound state is the same as the bound state, when this 
glycine is mutated to a leucine, our binding energy calculation cancels out the 
repulsive energy between the leucine and its local backbone environment. To 
account for this weakness in our protocol, we calculate a folding energy for each 
chain of the complex (see METHODS). A total of 22 of the 55 mutations 
predicted to have favorable binding energies were removed from consideration 
because the energy of the individual chains increased by more than 1 kcal/mol. 
Out of the 33 mutations that passed our filters, two mutations from Gαi1 
and four mutations from the GoLoco motif were selected for biophysical 
characterization. Binding affinities were measured by labeling the GoLoco motif 
peptide with the fluorescent dye fluorescein and monitoring fluorescence 
polarization as a function of Gαi1 concentration. Four out of six mutations resulted 
in an increase in binding affinity, and in three cases the increase was greater 
than 1 kcal/mol (Table 2.2). The largest increase was from the mutation F529W, 
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which lowered the Kd from 95 nM to 5.9 nM (Figure 2.2). A model of one of the 
affinity-increasing mutations (E116L) is shown in Figure 2.3. In the wild-type 
structure, E116 is not involved in any hydrogen bonds with other protein atoms, 
and is partially shielded from water by leucine 518 on the GoLoco motif peptide. 
In the model of the mutant structure (E116L), the new leucine forms a close 
hydrophobic interaction with leucine 518, and the desolvation energy for complex 
formation is predicted by Rosetta to be −1.6 kcal/mol more favorable for the 
mutant than for the wild-type complex. 
The biggest discrepancy between the predicted and experimentally 
derived binding energies was observed for the mutation, Q508L, in the GoLoco 
peptide. Glutamine 508 is buried in the middle of the interface, and its side-chain 
forms a hydrogen bond with a buried water molecule as well as the backbone 
nitrogen of residue 40 on Gαi1. The water also makes hydrogen bonds with 
groups on Gαi1. The water was not included in the Rosetta simulations and 
Rosetta predicted the mutation to leucine to be favorable because the side-chain 
on the glutamine did not satisfy its hydrogen bonding potential in the Rosetta 
simulation. Experimentally, Q508L destabilizes binding by more than tenfold. In 
the future, the calculations may be improved by explicitly modeling buried water 
molecules. 
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Predicting affinity-enhancing mutations at the UbcH7–E6AP 
interface 
Over 30 residues interact across the UbcH7–E6AP protein–protein 
interface. The structure of E6AP in the unbound state is virtually identical to the 
conformation that it adopts when forming a complex.35  Likewise the UbcH7 fold 
observed in the UbcH7-E6AP complex is similar to that of numerous unbound 
structures of other ubiquitin conjugating enzymes.36  The interaction is dominated 
by a phenylalanine on UbcH7 (F63) that packs into a hydrophobic pocket on 
E6AP.35  Mutation of the phenylalanine to an alanine destabilizes binding by over 
3 kcal/mol.37  As with the GoLoco motif/Gαi1 system, each interface position was 
sequentially mutated to a non-polar amino acid and binding energies were 
calculated with Rosetta. Relatively few mutations are predicted to be stabilizing 
(Table 2.3). The residues that are packed around F63 are primarily hydrophobic 
and mutating them to larger non-polar amino acids leads to steric clashes. 
Thirteen mutations were predicted to stabilize binding by greater than 
0.5 kcal/mol and not destabilize the individual chains by more than 1.5 kcal/mol. 
Most of these mutations are located on the periphery of the protein–protein 
interface. 
Six mutations were selected for experimental characterization, D641Y, 
D641W, Q637W on E6AP and A98W, K64L, F63W on UbcH7. Again, a 
fluorescence polarization binding assay was employed to measure binding 
affinities but in this case a thiol-reactive bodipy fluorophore was used. Five of the 
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six mutations enhance binding. The A98W mutation lowers the Kd from 5 µM to 
190 nM (Table 2.2).  As with the mutations that enhanced affinity at the GoLoco 
motif–Gαi1 interface, these changes create new hydrophobic interactions across 
the interface. A model of the A98W mutation on UbcH7 is shown in Figure 2.3. 
The new tryptophan is predicted to pack against D641, Y645 and M653 on 
E6AP. 
Testing the protocol on other protein–protein complexes 
To further test our protocol we searched the literature for point mutations 
that replace a polar amino acid with a non-polar amino acid or increase the size 
of a non-polar amino acid and have an experimentally determined ∆∆G°binding. 
There are hundreds of point mutations characterized in the literature, but most of 
them involve mutation to alanine and therefore are not useful to our test. We 
identified 38 mutations from nine different protein complexes that fit our criteria, 
and Rosetta was used to predict the change in free energy of binding of each 
mutation.  Eight of the mutations were predicted to increase binding affinity by 
more than 0.5 kcal/mol and not destabilize the individual proteins by more than 
1.0 kcal/mol. Five of the eight did in fact enhance binding affinity. Of the 38 
mutations that were examined, there were two mutations that enhanced binding 
by more than 0.5 kcal/mol that were not predicted to increase affinity by Rosetta. 
Looking more closely at the mutations that were falsely predicted to 
enhance binding affinity, we noticed that in two cases the mutation removed a 
hydrogen bond across the protein interface.  The hydrogen bonding term used in 
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the Rosetta energy function evaluates both the distance and the angle of the 
hydrogen bond, and the energy falls off rapidly with small changes in distance or 
angle. This method may be too stringent when used to predict energy from 
unminimized crystal structures. If Rosetta considers the hydrogen bond to be 
less than ideal, the energetic penalty for removing it can be insignificant 
compared to the other energy terms, resulting in a false prediction that the 
mutation is stabilizing to the complex. If we add a third filter to our scheme that 
requires ∆∆G°binding of the hydrogen bond energy term to be zero or less 
following a mutation, then two of the false positive predictions are removed from 
our results but all five of the correct predictions remain intact. 
Allowing backbone and side-chain relaxation in the energy 
calculations 
All of the results presented so far were based on calculations in which only 
the side-chain of the residue being mutated was allowed to sample alternate 
conformations in search of lower energy structures. The neighboring residues 
were not allowed to relax to better accommodate the mutation and the unbound 
structures of the proteins were assumed to be identical to the bound structure. In 
reality, many proteins can relax to lower free energy conformation(s) in the 
unbound state, and binding energies are partially determined by how much free 
energy is needed to bring the protein into the bound conformation. To test if our 
protocol for identifying affinity enhancing mutations can be improved by allowing 
relaxation in the bound and/or unbound states, we performed a variety of 
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simulations in which different elements of structure were allowed to relax. In each 
case, the method being tested was used to predict the ∆∆G°binding of point 
mutations that replace a polar amino acid with a non-polar amino acid or 
increase the size of a non-polar amino acid. The test set included point mutations 
from our laboratory as well as from literature and included 57 mutations from 11 
different protein complexes. 
Seven protocols were tested in addition to the standard fixed backbone 
approach. We considered three levels of relaxation, and one additional energy 
term. The first flexibility option allows for the residues neighboring a mutated 
position to adopt alternate side-chain coordinates (repack neighbors). Low 
energy conformations are identified using Monte Carlo optimization of side-chain 
rotamers. The second flexibility option allows the interface side-chains of the 
unbound proteins to adopt alternate rotamers (relax unbound). This option is 
designed to more closely model the physical behavior of proteins by allowing the 
unbound proteins to adopt low energy side-chain conformations that may be 
incompatible with the bound state. The third flexibility option allows for backbone 
relaxation. Gradient-based minimization of backbone torsion angles, side-chain 
torsion angles and rigid-body orientation of the two proteins is used to identify 
small conformational changes that lower the energy of the complex or the 
unbound structures. Gradient-based minimization was performed with and 
without constraints derived from the wild-type structure. In both cases only small 
motions were observed; the backbone typically moved by less than 0.2 Å rmsd. 
The fourth option modified the energy function. Our standard energy function for 
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these studies has a Lennard-Jones potential with a damped repulsive term to 
compensate for the fixed backbone and rotamers.17  In one set of simulations 
with gradient-based minimization we used a stiffer repulsive term to more 
accurately model the energy required to bring two atoms near each other. These 
four options were combined in a variety of ways to test the effects of including 
backbone and side-chain relaxation on predicting ∆∆G°binding. 
We compared the protocols by examining the percentage of correctly 
predicted affinity enhancing mutations (true positives) and the percentage of 
recovery of the known stabilizing mutations (20 out of the 57 mutations were 
experimentally determined to be stabilizing). As before, we only considered 
mutations that were predicted to stabilize binding by more than 0.5 kcal/mol and 
have chain energies that increase by less than 1 kcal/mol. In addition, to be 
considered stabilizing there could not be a decrease in hydrogen bonding energy 
across the interface. In general, including more flexibility did not improve the 
results. With the standard protocol (no flexibility) 83% of the mutations that were 
predicted to be stabilizing were indeed stabilizing and the recovery of 
experimentally determined stabilizing mutations by modeling was 50%. When the 
side-chains were allowed to relax to new rotamers in the bound and/or the 
unbound state there was a fall off in performance (Table 2.4). The percentage of 
true positives was lower and the recovery rate was decreased as well. It is not 
straight forward to determine why relaxing the side-chains did not improve the 
predictions, but overall the results suggest that some of the relaxed side-chains 
were placed incorrectly, which can have significant effects on the calculated 
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binding energies. In side-chain prediction benchmarks Rosetta performs similarly 
to most other side-chain repacking algorithms, on average 70% of the residues 
with chi 1 and chi 2 torsion angles are modeled with chi 1 and chi 2 within 30 
degrees of the angles in the crystal structures. This indicates that we should 
expect some of the side-chains at the interface to be relaxed incorrectly when 
forcing mutations. 
To further examine the predictions with flexible side-chains we looked in 
detail at two mutations whose binding energies were predicted correctly with 
fixed side-chains, but were predicted incorrectly when allowing the side-chains to 
relax (Figure 2.4). Mutating aspartic acid 641 to a tryptophan enhances binding 
affinity between E6AP and UbcH7 by 0.9 kcal/mol. The fixed side-chain 
simulations accurately predict that this mutation will favor tighter binding. When 
the side-chains are allowed to relax the new tryptophan and lysine 96 on UbcH7 
adopt alternate rotamers that creates a new packing arrangement between the 
side-chains. This packing arrangement lowers the total calculated energy for the 
complex as a whole (in part because the internal energy of W641 and K96 drops 
by 1.9 kcal/mol), but it does not lower the calculated binding energy, or the 
energy across the interface of the complex.  A new steric clash is introduced 
between the side-chain of W641 and the backbone oxygen of residue 95 that 
makes the predicted change in binding energy unfavorable. This result highlights 
the interplay between the various energy terms in Rosetta. A drop in one energy 
term can lead to an increase in another. Small errors in how the terms are 
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balanced can lead to possible error in side-chain prediction and hence the 
calculated binding energy. 
Mutating threonine 662 to a phenylalanine destabilizes binding between 
E6AP and UbcH7 by 0.2 kcal/mol. The simulation with fixed side-chains predicts 
that this mutation will destabilize binding by 0.7 kcal/mol, in part because there is 
a steric clash between F662 and E60 on UbcH7. In the flexible side-chain 
simulations E60 adopts a new rotamer to make room for the phenylalanine, and 
binding is predicted to be stabilized by 3.0 kcal/mol. In the crystal structure of the 
wild-type protein E60 is making a strained hydrogen bond with its own backbone 
amide group. In the relaxed structure this hydrogen bond is broken and the 
amide is buried by the phenylalanine. This may be a scenario where Rosetta is 
not properly penalizing the burial of a polar group that has no hydrogen bond 
partners. Again, this result highlights the sensitivity of side-chain prediction and 
binding energy calculations to how the various energy terms are balanced. 
Gradient-based minimization was used in a variety of ways: without repacking, 
with repacking, and with relaxation of the unbound state plus repacking. In most 
cases the rate of true positives was equal if not better than the fixed backbone 
simulation. However, the recovery rate was generally lower with minimization. In 
one case, all the mutations predicted to be stabilizing were stabilizing, but the 
rate of recovery fell to 25%. The rate of recovery was probably lower because the 
energies of the wild-type structures were more favorable, making many of the 
mutations appear less favorable.
 43
 
DISCUSSION 
Overall, the results suggest that increasing buried hydrophobic surface 
and/or reducing buried hydrophilic surface is an efficient approach for enhancing 
protein–protein binding affinities. In addition, it is important that the mutations do 
not create large clashes, do not destabilize the individual chains, and do not 
remove key hydrogen bonds across the interface. With this approach we 
selected 12 point mutations for experimental characterization and showed that 
nine of them increase protein binding affinity. In addition, mutations from the 
literature that pass our filters have a greater than 60% chance of being 
stabilizing. These are encouraging results considering that most randomly 
chosen mutations at a protein interface will weaken binding affinity. 
Our energy filters do remove from consideration some mutations that 
increase protein–protein binding affinities. Our standard fixed-backbone protocol 
identified approximately half of the known stabilizing mutations from our test set. 
We were curious if adding more side-chain and backbone flexibility in our 
simulations would decrease the number of stabilizing mutations that were not 
identified. In particular, relaxation may allow clashes to be relieved with new 
amino acids and allow for lower binding energies. In general, we observed the 
opposite result. Relaxing the system lowered the energy of the wild-type 
interaction and made more mutations appear unfavorable. 
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It is difficult to determine why the protocols with more flexibility did not 
outperform the fixed system model. There may be a combination of reasons. 
First of all, a number of stability and structural studies have been done that 
demonstrate that point mutations result in little to no movement away from the 
wild-type crystal structure coordinates other than in the immediate area of the 
mutation.27; 38; 39  Secondly, the community-wide critical assessment of protein 
structure prediction test from 2004 demonstrates that while modeling has 
improved significantly over the past decade, it is still very difficult to refine a 
nearly correct protein model to a more correct model.40  It may be that our flexible 
backbone and side-chain relaxation procedures are incorrectly predicting the 
structure of the mutant; in this case they would not be expected to provide a 
better estimate of binding energy. Kortemme and co-workers when 
computationally modeling protein–protein energetic hot spots, noted that 
optimizing rotameric side-chain conformations did not significantly improve their 
predictions except for the case of staphylococcal enterotoxin C3 bound to the T 
cell receptor β chain, a low resolution structure.41  The improvement in this case 
seemed to be due to the changes made in the native complex. 
One potential downside of our approach for increasing binding affinity is 
that it may lead to lower protein solubility as more hydrophobic surface area is 
exposed on the surface of the protein. For the 12 mutations that we 
characterized we did not see any reduction in solubility as evidenced by gel 
filtration chromatography. However, it is unlikely that one could combine several 
mutations of this type and still have a highly soluble protein. In general, we feel 
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that our protocol will be most useful for finding one or two mutations that provide 
a 1 or 2 kcal/mol increase in binding affinity, and then combining these mutations 
with other types of mutations to provide a larger increase in affinity. 
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(a) (b)
 
 
Figure 2.1. Structures of protein complexes selected for experimental 
validation of computational protocol. (a) Gαi1 shown in purple with the 
GoLoco domain of the RGS14 protein shown in magenta. (b) E6AP shown in 
blue bound to UBCH7 shown in green. 
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Figure 2.2. Binding curves for select affinity increasing mutations compared to wild 
type for (a) Gαi1:GoLoco and (b) E6AP:UbcH7. 
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E116L 
(a) (b
E116 
A98W 
(c)
A98
(d)
Figure 2.3. Modeled structure of the affinity enhancing design for (a) E116L 
Gαi1 bound to wild type GoLoco compared to (b) the crystal structure of the 
wild type Gαi1 bound to wild type GoLoco and (c) the modeled structure of 
A98W UbcH7 bound to wild type E6AP compared to (d) the crystal structure 
of the wild type UbcH7 bound to wild type E6AP.. 
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F662 
W641
F662W641
Figure 2.4. Models for the mutations D641W and T662F at the interface of E6AP and 
UbcH7. (a) and (d) Wild type residues; (b) and (e) the mutations modeled without repacking
neighbors; (c) and (f) the mutations modeled with repacking the neighboring residues.  The 
calculated changes in binding energy are indicated.  Experimentally, D641W stabilizes 
binding (∆∆G°bind=-0.9 kcal/mol) and T662F destabilizes binding (∆∆G°bind=0.2 kcal/mol). 
T662 
(a) WT structure 
Green – E6AP, Blue – UbcH7 
D641 
(f) T662F – repack neighbors 
∆∆G°bind_calculated = -3.0 
(c) D641W – repack neighbors 
∆∆G°bind_calculated = 0.8 
(b) D641W – no repack neighbors
∆∆G°bind_calculated = -1.7  
(d) WT structure 
Green – E6AP, Blue – UbcH7  
(e) T662F – no repack neighbors 
∆∆G°bind_calculated = 2.2 
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Table 2.1.  Scanning for affinity enhancing mutations at the A:Gαi1 – B:GoLoco interface. 
Mutation ∆∆G°binda ∆∆G° chain Ab ∆∆G° chain B # neighborsc ∆∆G°h-bondd 
A:G203W -2.8 5.7 0 23 0 
A:E116W -2.4 1.2 0 12 0 
B:I497W -2.1 0 0.6 14 0 
A:E116F -1.8 1.7 0 12 0 
A:G203Y -1.8 3.1 0 23 -0.7 
A:R86F -1.7 -2.9 0 23 0 
A:G203F -1.7 4.4 0 23 0 
A:E116L -1.5 -0.7 0 12 0 
B:L524W -1.5 0 7.8 18 0 
A:V72W -1.4 0.1 0 25 0 
A:E116Y -1.3 0.9 0 12 -0.4 
A:E116I -1.1 0.6 0 12 0 
B:S510V -1.1 0 2.5 23 0 
B:L524F -1.1 0 9.2 18 0 
B:F529W -1.1 0 -2.4 16 0 
B:L518F -1 0 1.3 16 0 
B:L518Y -1.1 0 0.6 16 0 
A:V72F -1 -1.2 0 25 0 
B:Q508L -1 0 -8 26 0.8 
A:V72Y -1 -1.7 0 25 0 
A:G112W -1 3 0 16 0 
B:Q508I -1 0 -7.8 26 0.8 
B:S510W -0.9 0 3.7 23 0 
A:S252W -0.8 0.9 0 16 0 
A:S252Y -0.8 0.4 0 16 0 
A:N256W -0.8 1.6 0 16 0 
A:R242W -0.7 -1.1 0 27 -0.1 
A:Q147M -0.7 0.4 0 20 0 
A:R86W -0.7 -5.7 0 23 0 
A:R242Y -0.7 -1.4 0 27 0 
A:Q147L -0.7 -1.2 0 20 0 
A:G203M -0.7 4.5 0 23 0 
A:S246F -0.6 0.3 0 27 0 
A:E116M -0.6 1.2 0 12 0 
A:E116V -0.6 0 0 12 0 
B:V525W -0.6 0 -1.3 12 0 
A:Q147W -0.6 0 0 20 0 
A:Q147F -0.6 -0.7 0 20 0 
A:Q147Y -0.6 -0.7 0 20 0 
A:G203L -0.6 2.8 0 23 0 
A:G202F -0.6 7.9 0 26 0.1 
B:L518W -0.6 0 1.3 16 0 
B:R516F -0.6 0 -0.9 22 0.8 
A:K46M -0.5 0.2 0 29 0 
B:E498M -0.5 0 1.1 10 0 
A:N256M -0.5 0.4 0 16 0 
B:S510M -0.5 0 2.8 23 0 
A:A101Y -0.5 3.3 0 15 0 
A:S246Y -0.5 0.2 0 27 0 
A:R242F -0.5 -1.1 0 27 0 
A:A101F -0.5 3.8 0 15 0 
A:G203I -0.5 2.5 0 23 0 
A:F215W -0.5 -2 0 21 0 
A:V72M -0.5 -0.8 0 25 0 
B:R516Y -0.5 0 -2.3 22 0.8 
Mutations selected for biophysical study are highlighted in orange.  Mutations highlighted in gray were not 
considered for biophysical study because were predicted to destabilize the monomer. 
a Predicted change in binding energy (kcal / mol) with the Rosetta Energy function. 
b Predicted change in folding energy (kcal / mol) of the isolated chain. 
c Number of residues in the complex within 10Å of the mutation. 
d Predicted change in hydrogen bond energy across the interface.   
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Table 2.2. Binding Affinities for Experimentally Characterized Mutants 
 
Mutation ∆∆G°Rosetta ∆∆G°exp. Kdexp. (µM). 
wild type Gαi1:GoLoco 0 0 0.098 
Gαi1 E116L -1.5 -1.05 0.016 
Gαi1 Q147L -0.7 -0.84 0.023 
GoLoco Q508L -1 3.17 >20 
GoLoco L518Y -1.1 0.07 0.110 
GoLoco V525W -0.6 -1.16 0.014 
GoLoco F529W -1.1 -1.65 0.006 
wild type UbcH7:E6AP 0 0 5.0 
UbcH7 A98W -1.7 -1.9 0.19 
E6AP D641Y -1.7 -1.1 0.8 
E6AP D641W -1.7 -0.86 1.2 
UbcH7 K64L -0.7 -0.54 2.0 
UbcH7 F63W -0.6 0.79 16.9 
E6AP Q637W -0.6 -0.64 1.7 
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Table 2.3.  Scanning for affinity enhancing mutations at the E6AP – UbcH7 interface. 
 
Mutation ∆∆G°bind ∆∆G° chain A ∆∆G° chain B # neighbors ∆∆G°h-bond 
D:A92F -2.7 0 9 13 0 
D:K9W -1.8 0 1.6 12 0.2 
A:D641F -1.8 1.9 0 16 0.1 
A:D641Y -1.7 1.2 0 16 0.1 
A:D641W -1.7 2.1 0 16 0.1 
D:A98W -1.7 0 -0.1 15 0 
D:N31W -1.6 0 3.1 14 0 
D:L33W -1.5 0 3.2 22 0 
D:A92Y -1.5 0 7.3 13 0 
D:A92W -1.4 0 6 13 0 
D:L33F -1.1 0 0.2 22 0 
D:A98F -1.1 0 1.3 15 0 
D:A98V -1.1 0 2 15 0 
D:R6W -1.1 0 3.8 18 0.1 
D:A98Y -1 0 0.7 15 0 
A:L639Y -0.9 14.4 0 23 0 
D:K64L -0.7 0 -1 19 0 
A:M653W -0.7 -5.8 0 24 0 
D:N31M -0.6 0 1.7 14 0 
A:Q637W -0.6 -1.9 0 20 0 
D:P62I -0.6 0 7.7 26 0 
A:D641V -0.6 0.9 0 16 0.1 
D:R6Y -0.6 0 5 18 0.1 
A:S660W -0.6 13.8 0 17 0 
D:F63W -0.6 0 0.2 23 0 
D:N31I -0.5 0 0 14 0 
A:T656I -0.5 2.9 0 20 0 
D:E60I -0.5 0 -2.3 20 0.1 
D:P58W -0.5 0 4 18 0 
D:A92M -0.5 0 5 13 0 
A:T662M -0.5 -3.4 0 15 0.1 
 
Mutations selected for biophysical study are highlighted in orange.  Mutations highlighted in gray were not 
considered for biophysical study because were predicted to destabilize the monomer. 
a Predicted change in binding energy (kcal / mol) with the Rosetta Energy function. 
b Predicted change in folding energy (kcal / mol) of the isolated chain. 
c Number of residues in the complex within 10Å of the mutation. 
d Predicted change in hydrogen bond energy across the interface.   
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Table 2.4. Predicting affinity enhancing mutations with varying degrees of side chain and 
backbone flexibility. 
 
 % true positive % recovery (out 
of 20 possible) 
Default 83 50 
R 60 15 
RR 67 20 
M 89 40 
RM 67 20 
RRM 83 25 
RRM 2nd 100 15 
RRMncst 100 25 
Full LJ, RRM 63 50 
 
% true positive is the percentage of mutations predicted to increase affinity that actually 
increase affinity.  Mutations that disrupt hydrogen bonding across the interface or 
destabilize the monomers by more than 1 kcal / mol were filtered out.  % recovery is the 
number of correctly predicted affinity enhancing point mutations divided by the total 
number of experimentally determined affinity enhancing point mutations.  The test set 
contains 57 mutations (polar to hydrophobic, hydrophobic to bigger hydrophobic), 20 of 
which increase binding affinity.  
Default = fixed backbone and side chains (except for the site of mutation) 
M = minimize backbone 
R = repack neighbors 
RM = repack neighbors, minimize backbone 
RR = repack neighbors, relax unbound 
RRM = repack neighbors, relax unbound, minimize backbone 
RRM 2nd = RRM run a second time 
RRMncst = repack neighbors, relax unbound, minimize backbone with  
no constraints 
full LJ, RRM = full Lennard-Jones repulsion, repack neighbors, relax unbound, minimize 
backbone 
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Supplementary Figure 2.1. Comparison of the 2.2 angstrom structure of R14GL 
with the 2.7 angstom structure. Gα subunits were aligned and is shown in green 
ribbon. R14GL from 1KJY is shown in yellow sticks and the R14GL peptide from 
2OM2 is shown in purple stick form. GDP is shown in line form.  
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METHODS 
Rosetta 
All energy calculations and side-chain and backbone relaxation 
simulations were performed with the molecular modeling program Rosetta.33  
Rosetta's core full atom energy function is a linear sum of molecular mechanics 
and knowledge-based terms: a 6–12 Lennard-Jones potential, the Lazaridis-
Karplus implicit solvation model,42 an empirically based hydrogen bonding 
potential,31 backbone-dependent rotamer probabilities,43 a knowledge-based 
electrostatics energy potential, amino acid probabilities based on particular 
regions of Φ/ψ space, and reference energies that approximate the energies of 
amino acids in the unfolded state.44  Within Rosetta, there are several variations 
on this core energy function. For the studies described here, we primarily use a 
version of the energy function that was recently parameterized to best reproduce 
native sequences when redesigning whole proteins in fixed backbone simulations 
(command line option, -soft_rep_design, Rosetta v 2.1). This variation of the 
energy function significantly dampens repulsion energies to allow for small atom–
atom clashes that may be accommodated by small changes in side-chain and 
backbone conformation. See supplementary material of Dantas et al. for a 
complete description of this version of the Rosetta energy function. It is referred 
to as Rosetta_DampRep.17 
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Varying degrees of backbone and side-chain flexibility were used as 
described in RESULTS. Side-chain flexibility is modeled by allowing amino acids 
to adopt different rotamers. We use Dunbrack's backbone-dependent rotamer 
library supplemented with rotamers that vary chi 1 and chi 2 one standard 
deviation away from their most probable values.43  Low energy combinations of 
side-chain conformations are identified using Monte Carlo optimization with 
simulated annealing.44  Independent side-chain repacking simulations typically 
converge to very similar energies (standard deviation < 0.1 kcal/mol) but 
generally do not have identical structures. The structures are not identical 
because some amino acids have alternate conformations that are isoenergetic 
(in the Rosetta energy function) in the absence of non-local interactions. 
Hydroxyl hydrogen atoms can adopt three isoenergetic states, asparagine and 
glutamine flips are isoenergetic, and the tautamers of histidine are isoenergetic. 
Hydrogen atoms only contribute to the Lennard-Jones repulsion term in Rosetta 
and therefore it is common for two hydrogen placements to have equal energy. 
Small motions in backbone and side-chain conformation and rigid-body 
displacement were modeled using gradient-based minimization (the Rosetta 
energy function is differentiable) with a quasi-Newton method.33  Phi, psi, omega 
and chi angles for residues within 5 Å of the protein–protein interface were 
allowed to vary. To prevent large structural changes during the initial step of 
minimization, eight cyles of mimization were performed in which the weight on 
the repulsive energy term was ramped to 1 while distance constraints based on 
the starting structure were lowered from high strength to low strength. 
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Independent runs of gradient-based minimization converge to identical results 
when the starting structures are identical, however, in most cases the starting 
structures were not identical because Rosetta was used to repack hydrogen 
atoms and/or side-chains (see above) before performing minimization. Because 
the runs did not converge to identical structures or energies, 100 separate 
minimizations were performed and the lowest energy structure was used for 
calculating binding energies. 
The affinity increase protocol is located in the analyze_interface_ddg.cc 
file in the Rosetta code.  This protocol requires the input of a pdb and will 
determine which mutations to make at the interface.  The command lines used 
were: 
rosetta.gcc –s input.pdb –interface –affin_incr –Wpack_only –soft_rep_design –
intout name_output –ex1 –ex2 –extrachi_cutoff 1 
rosetta.gcc –s input.pdb –interface –affin_incr –Wpack_only –soft_rep_design –
intout name_output –ex1 –ex2 –extrachi_cutoff 1 –repack_neighbors  
rosetta.gcc –s input.pdb –interface –affin_incr –Wpack_only –soft_rep_design –
intout name_output –ex1 –ex2 –extrachi_cutoff 1 –repack_neighbors –
relax_unbound 
rosetta.gcc –s input.pdb –interface –affin_incr –Wpack_only –soft_rep_design –
intout name_output –ex1 –ex2 –extrachi_cutoff 1 –repack_neighbors –
relax_unbound –min_inter –no_cst 
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where Wpack_only instructs Rosetta to use the default energy weight from the 
simulated annealing protocol,  -soft_rep_design dampens the Lennard-Jones 
repulsion term,  -repack_neighbors relaxes the entire wild type interface as well 
as all residues that neighbor a mutation,  -relax_unbound relaxes all interface 
residues of the unbound structures,  –min_interface performs gradient based 
minimization on the side chains and backbone as well as rigid body docking, and 
–no_cst sets constraints (designed to direct the designed structure to keep the 
RMSD to the wild type structure small) to the most relaxed setting.  
Binding energy calculations 
Binding energies were calculated by subtracting the energy of the complex 
from the energies of the individual chains.  The energies of the individual chains 
is reported along with the binding energies to allow the identification of point 
mutations that are predicted to significantly destabilize the bound conformation of 
an individual chain.  In our simplest protocol only the mutated residue is allowed 
to relax to a different rotamer, and it is assumed to adopt the same conformation 
in the unbound state. Our next level of complexity is to allow residues 
surrounding the mutated residue to relax to alternate side-chain rotamers 
(repack_neighbors). If the repack_neighbors option is true, the binding 
calculation begins by optimizing the conformation of all the side-chains at the 
protein–protein interface in the wild-type structure. This minimized structure is 
used to calculate the binding energy of the wild-type structure and serves as the 
starting structure for calculating the binding energy of the mutated structure. 
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Before calculating the energy of the mutant complex, amino acids that are close 
enough to have non-zero energy with the mutated residue are allowed to relax to 
more favorable rotamers as identified by Rosetta's side-chain repacking routine. 
In the simplest case, the side-chains are assumed to adopt the same rotamer in 
the unbound state. If the relax_unbound option is specified, side-chains near the 
point of mutation are relaxed separately in the bound and unbound state. The 
same residues are also relaxed in the bound and unbound state in the wild-type 
structure. Our calculations do not take into account changes in conformational 
entropy, and therefore, the absolute values of the binding energy calculations for 
a single complex do not represent true free energies. However, changes in 
binding energy (energy mutant–energy wild-type) do represent changes in free 
energy if one assumes that the conformational entropies of the various states do 
not change significantly with the mutation. 
Our protocol with the most degrees of freedom allows side-chains to adopt 
alternative rotamers and performs gradient-based minimization on backbone and 
side-chain torsion angles and rigid-body displacement. The flexible backbone 
procedure begins by minimizing the wild-type complex. This serves as the 
starting point for the calculations with the mutant complexes. If the 
relax_unbound option is true, separate gradient-based minimization is performed 
on bound and unbound molecules. The protocol with full side-chain and 
backbone flexibility does not converge to the same result each time it is 
performed. A total of 100 separate simulations were performed and the lowest 
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energy wild-type and mutant complexes, as well as wild-type and mutant 
unbound chains were used to calculate binding energies. 
Construction and cloning of protein designs  
The DNA sequence for the GoLoco motif of RGS14 (residues 496–531) 
was cloned into pET21b as a C-terminal fusion to the small protein Tenascin. 
Tenascin was included to aid in the expression and purification of the peptide. 
The sequence for a hexahistidine tag was placed at the C terminus of the 
construct. Residue G498 of the wild-type GoLoco motif was mutated to a 
cysteine to enable the covalent labeling of the thiol-reactive fluorescent probe 6-
iodoacetamidofluorescein (6-IAF) (Molecular Probes). We used an N-terminal-
truncated, hexahistidine-tagged expression construct of human Gαi1 with the first 
25 codons of the Gα open reading frame removed, as described.34  UbcH7 and 
E6AP expression plasmids have been described.45  Point mutations were 
introduced using the QuickChange® site-directed mutagenesis protocol 
(Stratagene) and all vectors were verified by DNA sequencing. 
Protein purification 
GoLoco motif peptide was expressed either for 4 h at 37 °C or overnight at 
25 °C with 0.5 mM IPTG in the BL21(DE3) strain of Escherichia coli. Gαi1 was 
expressed overnight at 25 °C with 1 mM IPTG in the BL21(DE3) strain of E. coli. 
Cells were lysed using an Avestin emulsiflex and the resulting lysates were 
cleared by ultracentrifugation. The Gαi1 ∆N2 and RGS14-GoLoco motif-Tenascin 
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fusion proteins were purified using a HiTrap (Amersham Biosciences) column by 
eluting the protein with an imidazole step gradient, then followed by gel filtration 
with a Superdex-200 column (Amersham Biosciences). Proteins were 
concentrated using Vivaspin 20® centrifugal concentrators. E6AP and UbcH7 
were expressed and purified as described.45  Protein concentrations were 
determined by measuring absorbance at 280 nm. Extinction coefficients were 
calculated using the method described by Gill and von Hipple.46 
Fluorescence polarization binding analysis 
The thiol-reactive fluorescent probe 6-IAF (Molecular Probes) was 
conjugated to the unique cysteine on the GoLoco motif using the manufacturer's 
recommended protocol. GoLoco motif protein was concentrated to 100 µM then 
buffer exchanged into 50 mM Tris-Cl (pH 7.5) and 1 mM TCEP using a PD10 
desalting column. The PD10 eluate was stirred for 1 h at room temperature. A 
20 mM stock solution of 6-IAF suspended in dimethyl sulfoxide (DMSO) was 
diluted into the GoLoco motif protein solution to a tenfold molar excess and the 
conjugation reaction was allowed to proceed overnight, in the dark at 4 °C. 
Precipitate was pelleted and discarded, and 5 mM β-mercaptoethanol (β-ME) 
was added to quench the reaction. The supernatant containing fluorescein-
GoLoco motif protein was run over a PD10 column to separate free probe from 
labeled protein. The concentration of fluorescein-GoLoco motif protein was 
quantified using UV/Vis, taking readings at 280 and 495 nm for the protein and 
fluorophore, respectively. The Tenascin-GoLoco fusion protein was used in the 
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binding assays. The previously published dissociation constant for Gαi1 and 
GoLoco of 65 nM determined using surface plasmon resonance34 is in close 
agreement with the 95 nM that we obtained using fluorescence anisotropy. 
Fluorescence polarization assays were carried out on a Jobin Yvon Horiba 
Spec FluoroLog-3 instrument (Jobin Yvon Inc.) performed in L-format with the 
excitation wavelength set at 495 nm and the emission wavelength set at 520 nm. 
Titrations were performed using a 3 mm × 3 mm quartz cuvette with a starting 
volume of 200 µl. Fluorescein labeled wild-type or mutant GoLoco motif protein 
was diluted to 50 nM and the excitation and emission slit widths adjusted to give 
a fluorescence intensity >100,000 counts per second. Wild-type or mutant Gαi1 
was added in increasing volumes from a stock solution whose initial 
concentration depended on the strength of the interaction, generally having a 
concentration of 3–10 µM. Two to three polarization readings consisting of three 
averaged measurements were collected for increasing concentrations of Gαi1. 
Data were averaged and analyzed using a model for single site binding 
according to equation (1), which was incorporated into equation (2) to account for 
the observed polarization: 
(1) 
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where [A:B] is the concentration of fluorescein-GoLoco motif protein and Gαi1 
complex formed, [At] is the total concentration of fluorescein-GoLoco motif 
protein, [Bt] is the concentration of Gαi1, Kd is the dissociation constant for the 
interaction, Po is the polarization in the absence of Gαi1, Pmax is the maximum 
polarization observed when all fluorescein-GoLoco motif protein is bound to Gαi1, 
and Pobs is the measured polarization at a given concentration of Gαi1. The data 
were fit according to equation (2) using non-linear regression with SigmaPlot 
software to obtain fitted parameters for Kd, Pmax, and Po.  
A detailed protocol for the conjugation of the thiol-reactive fluorophore 
bodipy (507/545)-iodoacetamide (Molecular Probes) to UbcH7 has been 
described.45  Binding assays were performed essentially as described.45  Data 
analysis was performed as described in equations (1) and (2) above where [A:B] 
is the concentration of bodipy-UbcH7 and E6AP complex formed, [At] is the total 
concentration of bodipy-UbcH7 protein, [Bt] is the concentration of E6AP protein, 
Kd is the dissociation constant for the interaction, Po is the polarization in the 
absence of UbcH7, Pmax is the maximum polarization observed when all bodipy-
UbcH7 is bound to E6AP, and Pobs is the measured polarization at a given 
concentration of UbcH7. The data were fit according to equation (2) using non-
linear regression with SigmaPlot software to obtain fitted parameters for Kd, Pmax, 
and Po. Starting concentrations for bodipy-E2 depended on the extent of 
conjugated fluorophore and typically fell in the range of 0.5–2.0 µM. Manual 
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titrations were performed using wild-type and mutant E6AP(HECT) stock 
solutions that varied based on yield and strength of the interaction. All binding 
assays were performed at room temperature in 20 mM KH2PO4 (pH 7.0), 
150 mM NaCl, 5 mM β-ME. For each binding experiment, nine polarization 
readings were collected and averaged at 20 concentrations of E6AP(HECT). 
Gαi1-RGS14-GoLoco crystal structure 
The atomic coordinates used in this study are from a newly deposited 
crystal structure (PDB ID: 2OM2) of Gαi1 complexed with a 36 amino acid residue 
peptide of the GoLoco motif from RGS14 (residues r496–r530, numbered 
according to full-length rat RGS14 protein and previously described34). Crystals 
were obtained by vapor diffusion from sitting drops containing a 1:1 (v/v) ratio of 
protein solution (16.5 mg ml−1 Gαi1∆N25, and 1.5-fold molar excess R14GL 
peptide in 10 mM Tris buffer (pH 7.5), 1 mM MgCl2, 10 µM GDP, 5% glycerol) to 
well solution (1.55 M ammonium sulfate, 100 mM sodium acetate (pH 5.0), 10% 
glycerol). For data collection at 100 K, the solution containing the crystals was 
adjusted to 25% glycerol by 2% (v/v) stepwise increases in glycerol 
concentration. A native data set was collected on a single crystal on SER-CAT 
beamline 22-ID at the Advanced Photon Source at Argonne National Labs. All 
data were indexed and processed using DENZO and SCALEPACK.47  The 
structure of Gαi1·GDP·Mg2+ (PDB ID: 1BOF)48 was used as a molecular 
replacement model using the CCP4 program AMoRe.49  Model building was 
performed with the program O50 and the program CNS was employed for 
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simulated annealing and torsion angle refinement.51  The structure was refined to 
2.2 angstroms. 
This structure (PDB ID: 2OM2) provides a higher maximum resolution 
than that reported previously (PDB ID: 1KJY).34  There are some important 
similarities and differences that can be noted (see Supplementary Data Figure 
2.1). Briefly, the GoLoco motif “arginine finger” (Arg r516) maintains its previously 
described contacts with GDP. In addition, the carboxy-terminal portion of the 
GoLoco motif peptide maintains all its contacts with the all-helical domain of Gαi1, 
supporting our previous findings that the all-helical domain is important for Gα 
specificity. In the higher resolution structure, both Leu r530 and Phe r529 are 
ordered, with the side-chain of Leu r530 stacking with the ring of Phe r529. The 
switch regions of Gαi1 do not change their conformation. The most significant 
differences are seen in the N-terminal alpha-helix of the GoLoco motif that 
nestles between switch region II (α2 helix) and the α3 helix of Gαi1. His r513 has 
rotated out of the binding interface with its γ-carbon moving by 6.6 Å. This 
rotation results in a two amino acid frame shift in the preceding alpha helix. For 
example, the hydrogen bonds formed by Arg r506 in the initial crystal structure 
are now being formed by Gln r508. Arg r506 maintains hydrogen bonding 
distance to Gαi1. 
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ABSTRACT 
We automated a computational protocol designed to increase the binding 
specificity of a protein-peptide interaction.  A conserved 19-amino acid motif, 
termed the GoLoco motif, is able to bind with the G-alpha subunits from the 
adenylyl-cyclase-inhibitory subclass.  This motif acts as a guanine nucleotide 
dissociation inhibitor for the GDP-bound G-alpha proteins.  We selected a 
complex from these two protein families that includes the RGS14 GoLoco motif 
and the Gαi1 protein.  We sought to redesign this interface so that these proteins 
would interact in a comparable manner to the wild type complex but will no longer 
interact with the other protein family members or their wild type counterparts.  
The ability to manipulate complexes in signaling networks can be used to 
develop biosensors for live cell imaging or to rewire or inhibit cell signaling 
pathways.  Increasing the binding specificity of a protein has additional 
applications including developing novel affinity chromatography columns or 
improving the specificity of protein therapeutics.  Our protocol searches for 
mutations that disrupt the wild-type interaction, followed by optimizing the 
neighboring sequence positions on the partner protein in an effort to compensate 
for the destabilizing effects.  We experimentally characterized 8 selected 
designs.  3 of the 8 redesigned complexes have a tighter binding affinity than 
their mixed mutant-wild type counterparts, demonstrating successful redesign of 
binding specificity.  We recovered a binding affinity comparable to that of the wild 
type complex for 2 of the 8 designs, showing a redesigned protein-peptide 
complex can behave similarly to the wild-type complex.  We then selected a 
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design with a specificity switch, but not recovery of wild-type binding affinity.  We 
are able to add affinity enhancing mutations to the design in order to recover a 
wild-type binding affinity while achieving a specificity switch of approximately 
100-fold.  
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INTRODUCTION 
Computational design of protein-protein interactions is a rigorous test of 
our understanding of the energetics regulating protein-protein recognition.  The 
accurate manipulation of the free energy of binding for a given protein complex 
tests the energy function and computational search algorithm of protein design 
software.  The energy function must be detailed enough to have predictive 
power.  In addition the protocol needs to sufficiently sample conformational 
space.  In many cases, where designs contain only a few amino acid 
substitutions, a fixed-backbone approximation can be used, where the protein 
backbones coordinates come from the experimentally determined structure and 
are not allowed to vary.  Thus the only parts of the protein structure that will be 
modeled are the amino acid side chains, greatly reducing the degrees of freedom 
that need to be considered.  Even with this approximation it is important to 
adequately model the side chain torsion angles.  Amino acid side chains are 
represented in discrete conformations, or rotamers, based on the torsion angles 
that are most often seen in a sample of non-homologous structure coordinate 
files taken from the Protein Data Bank.1; 2  Destabilizing effects of a mutation can 
be incorrectly predicted or overestimated due to an insufficient sampling of side-
chain torsion angles.  We evaluated the energy function, search procedure and 
coverage of conformational space of our protocol by both designing amino acid 
sequences to stabilize desired interactions while at the same time disrupting the 
undesired interactions.    
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Several approaches have been used to successfully redesign protein 
binding specificity.  Shifman et al. redesigned the interface between calmodulin 
(CaM) and one of its native binding partners, smooth muscle myosin light chain 
kinase (smMLCK).3  The redesigned CaM maintains wild type-like binding affinity 
to smMLCK but binds less tightly to a group of other native binding partners.  
They were able to accomplish this using only positive protein design, by 
redesigning the CaM sequence to stabilize the desired interaction, and without 
using negative protein design, or designing a sequence to disrupt the undesired 
interactions.  The decrease in binding affinity for most of the undesired 
interactions ranges from approximately equal for a homologue of smMLCK to 
over 100 fold for a peptide containing a non-natural amino acid.  These are 
impressive results, but our goal was to redesign protein-protein interfaces so that 
the proteins will not interact with the homologous family members of their binding 
partner.  Additionally, the successfully redesigned CaM protein contain 8 
mutations at the interface.  Maintaining the biochemical function of a protein 
might be a challenge with this many mutations at a binding interface.  Havranek 
et al. took a different approach by combining positive and negative protein design 
to design specificity in coiled-coil interactions.4  This protocol selects amino acids 
by simultaneously considering how much the substitution stabilizes the desired 
interaction and destabilizes the undesired interactions.  While the results are 
quite impressive, this protocol could be difficult to implement with other protein 
interactions because it requires structures for all protein-protein complexes that 
either binding partner is a part of.  Kortemme et al. redesigned the interface of 
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the colicin E6 DNase-Im7 immunity protein complex5 using a protocol that also 
uses both positive and negative protein design.  Their goal was to create an 
orthogonal interface where the components of the redesigned complex do not 
interact with the components of the wild type complex.  The idea is that if a 
redesigned mutant protein will not interact with its wild type counterpart then this 
specificity might extend to homologous family members.  A design of this nature 
could allow the isolation of a specific protein-protein interaction from a large 
network of interactions.  Their protocol uses negative protein design to search for 
point mutations that will destabilize the wild type interactions followed by positive 
design to search for mutations that can compensate for the destabilizing effects.  
The destabilizing point mutation explicitly designs against the mutant protein-wild 
type protein interaction.  The other mixed complex, the wild type protein-mutant 
protein, is implicitly designed against in the same way that Shifman et al. 
redesigned the calmodulin binding specificity.3  It is not certain if this type of 
implicit negative design will accomplish the desired destabilization of the mixed 
complex.  In fact, Kortemme et al. combined two sets of orthogonal mutations to 
obtain the desired destabilization for both mixed protein-protein complexes.  In 
this case, the redesigned complex is significantly destabilized compared to  the 
wild-type interaction, however.  Recently Joachimiak et al. compared this same 
protocol to a protocol that uses rigid body docking about an axis of rotation to 
generate an ensemble of protein-protein complex structures.  They were able to 
design a hydrogen bond network at the interface of the colicin E6 DNase-Im7 
immunity protein complex using the rigid body docking protocol.6  This is the first 
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known example of a rationally designed hydrogen bond network confirmed by an 
x-ray crystal structure.  The redesigned complex does not recover wild type 
binding affinity.  A crystal structure of the redesign was used for a second round 
of design.  The resulting complex did regain wild type binding affinity but lost 
specificity against the mixed wild type-mutant complexes.  A third round of design 
added a point mutation that successfully destabilized one of the mutant protein-
wild type protein complexes by 300 fold.   
We automated the orthogonal design protocol proposed by Kortemme et 
al.5 in order to evaluate it with a protein peptide complex.  Our aim was to obtain 
a destabilization of the wild type-redesigned complexes while maintaining a 
binding affinity for the redesigned complex comparable to that of the wild type 
interaction.  We use the Rosetta protein design software7.  Kortemme et al. used 
essentially the same software, although it was maintained separately from 
Rosetta.  Rosetta was created for protein structure prediction8.  Rosetta has had 
tremendous success in the critical assessment of structure prediction 
experiments (CASP)9; 10 and was subsequently applied to protein docking 
prediction11; 12 and protein design.13  Rosetta has been applied to protein-protein 
interface design to predict the importance of amino acid residues at protein 
interfaces,14 to predict affinity enhancing point mutations,15 and to design peptide 
extensions that will increase buried surface area and enhance protein peptide 
binding affinity.16   
 We select the Gαi1 protein and RGS14 GoLoco motif for our model system.17  
The Gαi1-GoLoco interface, with over 1900 Ǻ2 of buried surface area, provides 
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both hydrophobic as well as limited electrostatic regions for redesign.  The 
GoLoco binds to both the Ras-like domain and the all-helical domain of the Gαi1 
protein, offering two distinctly separate and structurally diverse regions for 
design.   
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RESULTS 
Each residue at the protein-protein interface of the Gαi1-GoLoco model 
system was sequentially mutated to the twenty amino acids in silico and the free 
energy of the structure was predicted with the Rosetta energy function.  In cases 
where the mutation was predicted to destabilize binding of the protein-peptide 
complex, neighboring residues were redesigned in search of compensating 
mutations.  Neighboring residues were defined as any sequence position where 
a side chain heavy atom is within 5.5 Å of a side chain heavy atom on the 
mutated sequence position.  The residues on the partner protein were 
redesigned in an effort to maintain a binding affinity comparable to the wild type 
complex (Figure 3.1 (b)).  Neighboring residues on the same chain as the 
destabilizing point mutation were also redesigned to prevent destabilization of the 
protein from the point mutation.  In this way each destabilizing point mutation 
became an orthogonal design.  In order to evaluate the quality of the design, the 
free energy of binding was predicted for each redesigned complex as well as the 
mixed complexes.  The mixed complexes need to be destabilized with respect to 
the redesigned complex in order to achieve orthogonality (Figure 3.1 (a)).  
Binding energies were calculated by subtracting the calculated energy of each 
unbound protein from the calculated energy of the complex.  In the first round of 
calculations, the backbone and side chain conformations of the unbound proteins 
were assumed to be identical to those in the bound state.  The side chains of the 
redesigned residues were built by choosing the rotamer with the lowest energy 
when modeled in the context of the complex.  The backbone coordinates were 
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held fixed to those found in the crystal structure (PDB ID: 2OM2).  All structures 
being evaluated, including the wild type Gαi1-GoLoco complex, redesigned Gαi1-
GoLoco and the mixed complexes, were modeled independently to allow the 
redesigned residues to find the lowest energy rotamer for each complex.    
Selection of orthogonal designs for experimental 
characterization  
Each interface position was sequentially mutated to the 20 amino acids in 
search of destabilizing point mutations.  Each predicted destabilizing point 
mutation became a design.  We considered more than 1500 designs.  Searching 
for possible orthogonal designs, we narrow the results to designs with binding 
energy for the mixed complexes that are less favorable than the wild type 
complex.  The redesigned complexes should perform like the wild type 
complexes, so they need to have a binding affinity in the range of the wild type 
complex.  We searched the remaining designs for predicted change in binding 
energy approximately equal to zero.  Finally, we removed designs that alter 
residues on the Gαi1 protein or GoLoco motif that have been shown to play an 
important role in biochemical function. For example, the RGS14 GoLoco motif 
interacts with both the Ras-like, guanine nucleotide binding domain and the all-
helical domain of Gαi1.17  The Ras-like domain of Gαi1 contains a flexible region 
termed the switch II which is able to open and expose a large hydrophobic 
surface when guanosine diphosphate (GDP) is bound.18  Mutations in the switch 
II can alter the intrinsic GTPase activity of the Gαi119 so we try to avoid  designs 
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that require mutations in this region.  Additionally, we eliminate designs that alter 
Gαi1 or GoLoco residues that interact with the bound GDP.   
We found four designs that meet our criteria.  These four designs are 
comprised of mutations with different chemical properties.  Three of the designs 
contain hydrogen bond interactions.  The fourth design increases the buried 
hydrophobic surface area across the interface by replacing a polar residue with a 
hydrophobic residue.  In order to thoroughly evaluate our protocol we wished to 
characterize two additional categories of mutations; a charge reversal and a 
hydrophobic core redesign.  The Gαi1-GoLoco interface is largely hydrophobic, 
with most of the hydrophilic residues at the interface participating in stabilization 
of the nucleotide or backbone hydrogen bonds.  We find one possibility for a 
charge reversal design, which alters a residue in the switch II region of Gαi1.  
This charge reversal design (Gαi1 R208E and GoLoco E498R) was selected by 
eye and all complexes were predicted by Rosetta to be stabilizing.  Charge 
reversal designs can be a highly effective way to redesign binding specificity 
since other native binding partners for each protein have likely evolved to have 
complementary charges to the wild type, as long as they bind at the same 
location.  Charge reversal design has been successfully used to improve a 
biosensor specificity.20  We have a thorough understanding of the hydrophobic 
effect and have been able to model mutations that enhance the stability of 
monomeric proteins and protein complexes.15; 21  We therefore add four 
hydrophobic core designs (Figure 3.2 panels c,d,g and h).   
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Experimental characterization of orthogonal designs 
Of the four designs that passed our initial filters, experimental validation 
showed that two designs retain a binding affinity comparable to the wild type 
complex.  Those are design 1, Gαi1 E245L,L249A and GoLoco V507M, and 
design 2, Gαi1 K248E,S252L and GoLoco L503K.  (Figure 3.2 panels a and b).  
Additionally, both designs have higher binding affinity for the redesigned 
complexes than for the mixed complexes, although the specificity switch is 
modest.  One of the designs, design 1 (Gαi1 E245L,L249A and GoLoco V507M),  
is stabilized relative to the wild type complex. (Table 3.1 and Figure 3.3)  This 
redesigned Gαi1 (Gαi1 E245L,L249A) with the wild type GoLoco has a binding 
affinity comparable to that of the wild type complex.  The redesigned GoLoco 
(GoLoco V507M) with the wild type Gαi1 is destabilized by approximately one 
order of magnitude.  Thus the desired specificity was achieved, but only in one 
direction.  (∆∆G°bind Table 3.1 design 1 and Figure 3.3 - Gαi1 E245L,L249A and 
GoLoco V507M)  The second design does have the desired specificity switch 
(∆∆G°bind in Table 3.1 design 2 and Figure 3.3 - Gαi1 K248E,S252L and GoLoco 
L503K).  Design 2 (Gαi1 K248E,S252L and GoLoco L503K) is located on the 
periphery of the interface and introduces an electrostatic interaction across the 
interface accommodated by a charge reversal on the Gαi1.  The specificity switch 
for this design is modest.  The remaining two designs were predicted to bind 
similarly to the wild type complex but were in fact destabilized by close to two 
orders of magnitude.  Both contain designed hydrogen bonds.  The hydrogen 
bonds in these designs are not ideal in their distance or angle.22 (Figure 3.2)   
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Only one of the ten designs was not characterized due to a protein, 
GoLoco F529P,L530Y, that was insoluble.  One design, Gαi1 I78S,A111Q and 
GoLoco L519T, was not fully characterized when the redesigned structure 
measured a binding affinity estimated to be greater than 45 µM.    Of the 
remaining 8 designs, three have the specificity intended by the protocol, where 
the redesigned complex binds more tightly than the mixed complexes.  5 of the 8 
exhibit specificity in at least one direction, in that the redesigned complex binds 
more tightly than at least one of the mixed complexes. (Figure 3.3).  These 
results are encouraging given that the design protocol explicitly designs 
specificity in only one direction due to the destabilizing point mutation.  Ideally the 
compensating mutations made on the opposite chain would destabilize the 
interaction with its wild type counterpart.  This is based on the work by Shifman 
et al. who were able to achieve increased specificity with calmodulin simply by 
redesigning the wild type interaction with smooth muscle myosin light chain 
kinase3.   
Combining affinity enhancing mutations with orthogonal 
designs 
The results for design 2, are encouraging given that specificity was 
achieved and the redesigned complex maintained the desired binding affinity.  
Applying this protocol to design biosensors or rewire a cellular network may 
require a larger specificity switch than was achieved with designs 1 and 2.  It is 
difficult to know what binding specificities are needed to maintain desired 
interactions while inhibiting undesired interactions without knowing the kinetics of 
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all relevant protein interactions as well as the cellular protein concentrations.  We 
therefore wanted to see if we could design a complex that could maintain the 
biochemically relevant binding affinity while achieving more destabilization of the 
wild type-mutant mixed complexes.  Kortemme et al., using the protocol that this 
work is based on, combined two designs in order to weaken binding for both 
mixed complexes.5  The specificity switch was modest and the redesigned 
complex was destabilized compared to the wild type complex.  We have two 
designs that bind similarly to the wild type.  These designs are immediately 
adjacent to one another.  We therefore looked for an alternative approach.   
We have developed a protocol to efficiently predict point mutations to 
enhance protein-protein binding affinity.  Looking for an approach to develop an 
orthogonal design with the desired specificity we try combining affinity enhancing 
mutations with orthogonal designs to bring the binding affinity of the redesigned 
complex into the range of the wild type complex.  The designs that did not pass 
our initial filters were not predicted to bind with an affinity comparable to the wild 
type complex and they do not.  Three of these designs did achieve at least partial 
specificity.  We selected design 6 (Gαi1 I78A,A111F and GoLoco L519G,L524T) 
and design 7 (Gαi1 F223V,L249F and GoLoco L504A) to combine with affinity 
enhancing point mutations Gαi1 E245L, Gαi1 Q147L and GoLoco F529W.  Design 
6 has the desired specificity but the redesigned complex is destabilized by an 
order of magnitude.  The binding affinity of design 6 is not enhanced by any of 
the mutations tried, however.  (Table 3.2)  Perhaps the GoLoco L519G mutation 
has an entropic effect that is not compensated for by the affinity enhancing 
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mutations.  Design 7 is selected because it is a simple hydrophobic core 
redesign and may be simpler to manipulate with affinity enhancing mutations.  
The addition of the Gαi1 Q147L mutation brings the dissociation constant down 
from greater than 2 µM to 1.1 µM.  Combining this with the Gαi1 E245L mutation 
brings the dissociation constant down to 0.14 µM, within the range of the wild 
type (see Figure 3.4 and Table 3.2).  Thus a specificity switch of approximately 
17 fold has been achieved while maintaining a binding affinity similar to the wild 
type.  Adding one final affinity enhancing point mutation, F529W on the GoLoco 
domain, brings the dissociation constant down to 0.04 µM and the dissociation 
constant for the GoLoco V507M,F529W with the wild type Gαi1 is measure at 
greater than 5 µM, giving a specificity switch of greater than 125 fold against the 
redesigned GoLoco domain.  (Figure 3.5)  Joachimiak et al. obtained a specificity 
switch of approximately 300 fold.6  They reported designing a hydrogen bond 
across a protein-protein interface, but destabilized the complex with respect to 
wild type.  Solving the crystal structure of the design they performed a second 
round of design to recover binding affinity, followed by a third design where they 
added a single mutation to obtain the 300 fold specificity switch.   
Varying levels of side chain flexibility in predicting ∆∆G°bind 
The first round of calculations maintained the same backbone and side 
chain conformations for the unbound proteins and the bound state.  The side 
chains that were allowed to vary their identity were the only side chains allowed 
to search for lower conformational states.  The results are shown in Table 3.1.  It 
is possible that residues neighboring computational mutation sites could also find 
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lower energy conformations, relieving steric clashes or improving hydrogen 
bonds.  The command for this protocol is –repack_neighbors.  We also consider 
the interface residues could find lower energy conformation in the unbound 
structures, termed –relax_unbound.  We combine –repack_neighbors and –
relax_unbound to get maximum side-chain flexibility.  This protocol with 
increased flexibility did not improve the predictions for electrostatic interactions, 
as seen with designs 2 and 3. (Supplementary Table 3.1)  The redesigned 
complexes for designs 1 and 2 were correctly predicted to be affinity enhancing, 
although with only two data points it is not clear what led to the improvement.  
Overall the results from the initial protocol which only models amino acids 
allowed to change identity are comparable to the more computationally 
expensive protocols that allow for more extensive redesign.   
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DISCUSSION 
One of the four designs that passed our set of filters was in fact a 
modestly orthogonal interface.  The redesigned proteins bound with less affinity 
to the wild type binding partners than the redesigned or wild type complexes.  A 
second design gave a specificity switch of one order of magnitude against the 
redesigned GoLoco motif only.  Additionally, both of these redesigned complexes 
bound with a binding affinity similar to that of the wild type complex.  The results 
of this work demonstrate that the specificity of a protein peptide complex can be 
redesigned using this simple approach, introducing a destabilizing point mutation 
at the interface and designing compensating mutations around it.  These results 
also suggest that there is reasonable predictive power with the Rosetta energy 
function.  The specificity switch for the initial round of designs is modest, 
however.  Redesigning protein-protein binding specificity is a hard problem.  
Applying this protocol to the Gαi1-GoLoco interface, which buries approximately 
1900 square angstroms of surface area, resulted in more than 1500 designs.  Yet 
only 4 designs passed our filters. Of the designs selected for experimental 
characterization that did not pass our initial set of filters, none recovered wild 
type binding affinity.  One possibility is that it is very difficult to find amino acids 
that can compensate for the introduction of a destabilizing point mutation.  This 
can be seen in the quality of hydrophobic packing and hydrogen bonds in the 
designs (Figure 3.6).  The incorporation of small backbone movements in the 
design protocol could increase the sequence space that is sampled, thereby 
increasing the number and quality of the designs.  Our work automating a 
 88
protocol to predict affinity enhancing mutations evaluated a gradient based 
backbone and side chain minimization method.15  We did not, however, see 
significant improvement in the predictive power of the protocol.  Davis et al. found 
that the reorientation of two consecutive peptide backbone torsion angles, 
termed backrub motion, could significantly could alter accessible side chain 
conformations and greatly improve interactions in crystal structures.23  Adding 
movement of the backbone torsion angles such as the backrub motion might 
increase the sequence space that is sampled, thereby improving the quality of 
the designs.  At least five research groups including ours have addressed this 
problem in a variety of ways.3; 4; 5; 6; 24  The most impressive results to date are 
those by Joachimiak et al. who implemented backbone movement in the form of 
rigid body docking of the protein-protein complex, ultimately achieving a 
specificity switch of approximately 300 fold.6  These results were achieved after 
solving the crystal structure of the first design, followed by two additional rounds 
of design.   
While the results of our orthogonal design are encouraging, if this protocol 
were applied to rewire a cellular network or develop a biosensor, any undesired 
protein-protein interactions decrease the accuracy of these tools.  It is difficult to 
know exactly how much destabilization of the mixed complexes is required 
without knowing the kinetics of all involved protein-protein interactions as well as 
cellular protein concentrations.  We therefore wanted to achieve greater 
destabilization of the redesigned protein – wild type protein complexes while still 
maintaining a wild type binding affinity to evaluate how much specificity we could 
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achieve with this protocol.  Many of the designs that did not recover wild type 
binding affinity did achieve significantly more destabilization of the mixed 
complexes.  By combining the protocol to predict affinity enhancing point 
mutations with the specificity redesign protocol we were able to create a 
redesigned complex that maintained wild type binding affinity with a specificity 
switch of 17 fold against one of the mutant protein-wild type protein complexes.  
An additional affinity enhancing mutation gave the same complex a specificity 
switch of at least 125 fold against the redesigned GoLoco domain.  This 
redesigned complex has four mutations on the Gαi1 protein 
(Q147L,F223V,E245L,L249F) and two mutation on the GoLoco peptide 
(V507M,F529W).   
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Figure 3.2.  Modeled structures of orthogonal designs selected for experimental 
characterization. (a) Design 1: Gαi1 E245L, L249A and GoLoco V507M, (b) 
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Design 2: Gαi1 K248E, S252L and GoLoco L503K, (c) Design 3: Gαi1 F223V, 
L249F and GoLoco L504A, (d) Gαi1 I78A, A111F and GoLoco L519G, L524T, (e) 
Gαi1 F215K and GoLoco L500E, (f) Gαi1 I78S, A111Q and GoLoco L519T, (g) 
Gαi1 I253T and GoLoco L504Y, (h) Gαi1 I253C and GoLoco L504W, (i) Gαi1 
R208E and GoLoco E498R. 
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Figure 3.3.  Binding curves for experimentally characterized orthogonal designs.                             
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Figure 3.5.  Specificity of design 7 with addition of affinity enhancing mutations, 
Gαi1 F223V,L249F,Q147L,E245L and GoLoco L504A,F529W  
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modeled hydrogen atoms shown. 
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Table 3.1.  Predicted and experimentally characterized binding energies for 
orthogonal designs selected for experimental characterization. 
 
 Design Gαi1 mutations 
GoLoco 
mutations ∆∆G°Rosetta ∆∆G°bind 
Kd 
exp 
Std Dev 
exp 
 Wild type wild type 0 0 0.10 0.02 
1 E245L,L249A V507M 0.1 -0.41 0.05 0.01 
 E245L,L249A wild type 2 0.24 0.15 0.03 
 Wild type V507M 0.6 1.39 1.04 0.06 
2 K248E,S252L L503K 0.3 -0.13 0.08 0.001 
 K248E,S252L wild type 0.4 0.69 0.32 0.06 
 Wild type L503K 2.5 0.52 0.24 0.02 
3 F215K L500E 0.1 >2 >3 4.9 
 F215K wild type 0.3 >2.3 >5 12.9 
 Wild type L500E 0.4 - 
no binding 
detected 
4 I78S,A111Q L519T -0.5 >3 >17 56 
 I78S,A111Q wild type 0.9 - not characterized 
 Wild type L519T 0.9 - not characterized 
5 R208E E498R -4.9 2.02 3.03 0.47 
 R208E wild type -3.7 2.64 8.55 1.63 
 Wild type E498R -1 -1.37 0.01   
6 I78A,A111F L519G,L524T 1.2 1.73 1.85 1.65 
 I78A,A111F wild type 0.5 1.99 2.87 0.57 
 Wild type L519G,L524T 1.9 >2.6 >8 15.22 
7 F223V,L249F L504A 1.5 >1.8 >2 64.3 
 F223V,L249F wild type 108.7 >2 >3 23.7 
 Wild type L504A 1.5 1.89 2.41 0.95 
8 I253T L504Y 6.1 2.14 3.67 0.60 
 I253T wild type 0.8 0.92 0.47 0.07 
 Wild type L504Y 437.9 2.13 3.60 0.63 
9 I253C L504W 84.8 >2.3 >5 21.6 
 I253C wild type 0.8 0.95 0.50   
 Wild type L504W 220.5 1.99 2.85 0.23 
10 F95H,A101W F529PL530Y 3.1 - not characterized 
 F95H,A101W wild type 0.1 - not characterized 
 wild type F529PL530Y 14.7 - insoluble 
8.5 L249A,I253C L504W   1.82 2.16 0.21 
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Table 3.2. Experimentally determined binding energies for designs 6 and 7 with affinity 
enhancing mutations. 
  Gαi1 mutations GoLoco mutations Kd exp. 
Standard 
Deviation 
exp. 
  wild type wild type 0.10 0.02 
Design 7 F223V,L249F L504A >2 64 
  F223V,L249F wild type >3 24 
  wild type L504A 2.41 0.95 
.+ Q147L F223V,L249F,Q147L L504A 1.10 0.5 
  F223V,L249F,Q147L wild type >3.5 3.4 
  wild type L504A 2.41 0.95 
.+Q147L, F223V,L249F,Q147L,E245L L504A 0.14 0.05 
.+E245L F223V,L249F,Q147L,E245L wild type 0.09 0.01 
  wild type L504A 2.41 0.95 
.+Q147L, F223V,L249F,Q147L,E245L L504A,F529W 0.04 0.01 
.+E245L, F223V,L249F,Q147L,E245L wild type 0.09 0.01 
.+F529W wild type L504A,F529W >5 - 
Design 6 I78A,A111F L519G,L524T 1.85 1.65 
  I78A,A111F wild type 2.87 0.57 
  wild type L519G,L524T >8 15 
.+E245L I78A,A111F,E245L L519G,L524T >7.5 2956 
.+F529W I78A,A111F  L519G,L524T,F529W >2.7 3.8 
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Supplementary Table 3.1.  Computationally predicting ∆∆Gbind with varying degrees of 
side chain flexibility. 
 
  
Gαi1 
mutations 
GoLoco 
mutations 
∆∆G°Rosetta 
(default) 
∆∆G°Rosetta 
(RN,RU) ∆∆G°bind 
  wild type wild type 0 0 0 
Design 1 E245L,L249A V507M 0.1 -1.6 -2.05 
  E245L,L249A wild type 2 -2.2 -0.72 
  wild type V507M 0.6 12.6 0.28 
Design 2 K248E,S252L L503K 0.3 -0.2 -0.10 
  K248E,S252L wild type 0.4 16.7 0.72 
  wild type L503K 2.5 2.8 0.55 
Design 3 F215K L500E 0.1 -1.3 >2 
  F215K wild type 0.3 0.7 >2.3 
  wild type L500E 0.4 -0.7 - 
Design 4 I78S,A111Q L519T -0.5 -0.1 >3 
  I78S,A111Q wild type 0.9 21.6 - 
  wild type L519T 0.9 0.3 - 
Design 5 R208E E498R -4.9 0.3 2.05 
  R208E wild type -3.7 1.5 2.67 
  wild type E498R -1 0.3 -1.40 
Design 6 I78A,A111F L519G,L524T 1.2 2.5 1.76 
  I78A,A111F wild type 0.5 141.2 2.02 
  wild type L519G,L524T 1.9 3.3 >2.6 
Design 7 F223V,L249F L504A 1.5 0.4 >1.8 
  F223V,L249F wild type 108.7 215.4 >2 
  wild type L504A 1.5 1 1.92 
Design 8 I253T L504Y 6.1 3 2.17 
  I253T wild type 0.8 -0.9 0.95 
  wild type L504Y 437.9 35.9 2.16 
Design 9 I253C L504W 84.8 29.8 >2.4 
  I253C wild type 0.8 -1 0.99 
  wild type L504W 220.5 335.2 2.02 
Design 10 F95H,A101W F529PL530Y 3.1 17.3 - 
  F95H,A101W wild type 0.1 0.8 - 
  wild type F529PL530Y 14.7 25.2 - 
Design 8.5 L249A,I253C L504W     1.85 
 
∆∆G°Rosetta (default) = fixed backbone and side chains (except for the site of mutation) 
 
∆∆G°Rosetta (RN,RU) = repack neighbors, relax unbound 
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METHODS 
 
Rosetta 
All energy calculations and side chain and backbone relaxation 
simulations were performed with the molecular modeling program Rosetta7.   
We used the following command lines to run the alter_spec protocol and 
generate sets of mutations designed to alter binding specificity. 
 
The command line for design 1 (Gαi1 E245L,L249A and GoLoco V507M): 
 
 
rosetta.gcc –s gpep1.pdb –design –alter_spec –alter_spec_mutlist mutlist.   
 
 
The input pdb, gpep1.pdb, is from the crystal structure 2OM2.  The mode of 
rosetta used is the protein design mode, indicated by –design.  The specific 
protocol used in design mode is alter_spec.  The output file containing the sets of 
mutations selected is renamed using the –alter_spec_mutlist command and is 
renamed to mutlist.    
 
The GoLoco mutation V507M was predicted to significantly destabilize the 
interaction due to van der Waals clashes.  The experimental characterization 
demonstrated that this mutation did not significantly destabilize the Gαi1:GoLoco 
interaction.  Methionine is a very flexible residue and was probably not 
represented by enough rotamers, or discrete representations of side-chain 
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conformations1, resulting in an incorrect prediction.  Negative protein design 
requires a large rotamer library, and so we added the command 
“select_rotamer_set = large” to the code.   
  
Design 2 (Gαi1 K248E,S252L and GoLoco L503K), design 3 (Gαi1 F215K and 
GoLoco L500E), design 6 (Gαi1 I78A,A111F and GoLoco L519G,L524T)  and 
design 7 (Gαi1 F223V,L249F and GoLoco L504A) were generated using the 
following command line: 
 
rosetta.gcc -s gpep1.pdb –design –alter_spec –alter_spec_mutlist 
mutlist_10_2_fix –fix fix_9_17 
 
The –fix command allows for a file to be read into the program that specifies 
residues which are not to be mutated.  In this case the file was named fix_9_17 
and included residues 39,40,41,42,43 and 178 from the Gαi1 and residues 
508,514,515 and 516 from the GoLoco.  These residues have been shown to 
contact or be important in stabilizing the bound nucleotide or appear to form 
hydrogen bonds with a backbone residue.  A design run was also performed 
using the –fix input file to hold fixed the Gαi1 residues that are in the region 
termed switch II, as mutations in this region can alter the intrinsic GTPase 
activity19.  Limiting the number of residues that may be used in a redesign 
decreased the total number of output designs but did not alter the designs that 
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were generated and so no designs were selected for experimental 
characterization from this run.    
Design 4 (Gαi1 I78S,A111Q and GoLoco L519T) and design 10 (Gαi1 
F95H,A101W and GoLoco L529P,L530Y) were generated using the following 
command line: 
 
rosetta.gcc –s gpep1.pdb –design –alter_spec –alter_spec_mutlist mutlist –ex1 –
ex2 –ex3 
 
The –ex1 –ex2 and –ex3 flags are used to increase the rotamer library by adding 
rotamers that are expanded about the chi 1, chi 2 and chi 3 angles respectively.   
Design 10 (Gαi1 R208E and GoLoco E498R) was selected by eye.  It was 
selected because it is a charge-swap design and the alter_spec runs did not 
produce any clear charge-exchanging designs. 
Binding Energy Calculations 
The second step in our protocol computationally evaluates the ∆∆Gbinding 
of all the designs produced in the alter_spec run.  This protocol is called 
analyze_interface and can be found in the analyze_interface_ddg.cc file in the 
code.  This command lines used are as follows: 
 
(1) rosetta.gcc –s gpep1.pdb –interface –Wpack_only –repack_neighbors –
alter_spec_format –mutlist mutlist –intout intout –output_structure –ex1 –ex2 –
ex3  
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(2) rosetta.gcc –s gpep1.pdb –interface –Wpack_only –repack_neighbors –
soft_rep_design –alter_spec_format –mutlist mutlist –intout intout –
output_structure –ex1 –ex2 –ex3  
(3) rosetta.gcc –s gpep1.pdb –interface –Wpack_only –repack_neighbors –
relax_unbound –soft_rep_design –alter_spec_format –mutlist mutlist –intout 
intout –output_structure –ex1 –ex2 –ex3  
 
We evaluated the designs by comparing the predicted ∆∆Gbinding results 
from runs using different combinations of commands for the analyze_interface 
protocol, ranging from the most conservative (shown by command line 1 above), 
which designs only the residues that will alter their identity, to more flexible where 
the wild type interface is relaxed as well as all residues that neighbor mutation 
sites and all interface residues on the unbound structures (command line 3 
above).  The –interface flag indicate the rosetta mode designed to predict the 
free energy of binding for two proteins given structural coordinates and a list of 
mutations.  The file containing a list of mutations is the file title mutlist.  The 
output file can be renamed using the –intout command, with the name 
immediately following the command.  The –output_structure command specifies 
that the structures generated, both wild-type and mutant, be output as pdb files.  
The –Wpack_only command specifies that the energy function used for both 
modeling and energy prediction is the rosetta energy function that has been 
parameterized to reproduce native amino acid sequences.  The default energy 
function for the –interface mode was parameterized to predict experimentally 
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determined ∆∆Gbinding data from alanine scan studies culled from literature25.  
The -repack_neighbors flag indicates that any residues neighboring a mutated 
residue should be allowed to relax.  The –relax_unbound flag allows all residues 
at the protein-protein interface to relax in the unbound structure.  The –
relax_unbound flag will only be utilized if –repack_neighbors and/or 
min_interface is also indicated in the command line.  The reason can be 
understood when considering how analyze_interface determines the 
computational ∆∆Gbind;  
 
∆∆Gbind=∆Gmutant-∆Gwild type 
where ∆Gmutant= Gmut complex-Gmut chA-Gmut chB 
and ∆Gwild type = Gwt complex – Gwt chA – Gwt chB. 
 
The analyze_interface protocol by default only moves residues that are changing 
identity; ideally this would be only three to six residues.  The repack_neighbors 
flag, on the other hand, moves all residues at the protein-protein interface.  If a 
user were to use the repack_neighbors flag in the default mode then the 
predicted energy of the unbound structures could be significantly lowered and 
might no longer compare to the predicted energy of the crystal structure 
coordinates, resulting in a significant and artificial increase in the number of 
positive ∆Gmutant and ∆Gwild type predictions.   The repack_neighbors flag not only 
allows all residues determined to be neighbors of a mutated residue to adopt a 
lower-energy conformation but also relaxes the entire wild-type interface.  Thus 
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the bound and unbound structures should start from the same or very similar 
conformations.  The –soft_rep_design flag dampens repulsion energies to allow 
for small atom-atom clashes that may be accommodated by small changes in 
side chain and backbone conformation.  The –alter_spec_format flag outputs the 
results in a format that visually clusters the results by design, with the 
mutant:mutant, mutant:wild-type and wild-type:mutant ∆∆Gbind are grouped. 
 Binding energies were calculated by subtracting the energy of the complex 
from the energies of the individual chains.  In our simplest protocol only the 
mutated residue is allowed to relax to a different rotamer, and it is assumed to 
adopt the same conformation in the unbound state.  Our next level of complexity 
is to allow residues surrounding the mutated residue to relax to alternate side 
chain rotamers (repack_neighbors).  If the repack_neighbors option is true, the 
binding calculation begins by optimizing the conformation of all the side chains at 
the protein-protein interface in the wild type structure.  This minimized structure is 
used to calculate the binding energy of the wild type structure and serves as the 
starting structure for calculating the binding energy of the mutated structure.  
Before calculating the energy of the mutant complex, amino acids which are 
close enough to have non-zero energy with the mutated residue are allowed to 
relax to more favorable rotamers as identified by Rosetta’s side chain repacking 
routine.  In the simplest case, the side chains are assumed to adopt the same 
rotamer in the unbound state.  If the relax_unbound option is specified, side 
chains near the point of mutation are relaxed separately in the bound and 
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unbound state.  The same residues are also relaxed in the bound and unbound 
state in the wild type structure.   
 Our protocol with the most degrees of freedom allows side chains to adopt 
alternative rotamers and performs gradient-based minimization on backbone and 
side chain torsion angles and rigid body displacement.  The flexible backbone 
procedure begins by minimizing the wild type complex.  This serves as the 
starting point for the calculations with the mutant complexes.  If the 
relax_unbound option is true, separate gradient based minimization is performed 
on bound and unbound molecules.  The protocol with full side chain and 
backbone flexibility does not converge to the same result each time it is 
performed.  100 separate simulations were performed and the lowest energy wild 
type and mutant complexes, as well as wild type and mutant unbound chains 
were used to calculate binding energies.  
Construction and cloning of protein designs  
The DNA sequence for the GoLoco motif of RGS14 (residues 496-531) 
was cloned into pET21b as a C-terminal fusion to the small protein Tenascin.  
Tenascin was included to aid in the expression and purification of the peptide.  
The sequence for a hexahistidine tag was placed at the C-terminus of the 
construct.  Residue G498 of the wild type GoLoco motif was mutated to a 
cysteine to enable the covalent labeling of the thiol-reactive fluorescent probe 6-
iodoacetamidofluorescein (6-IAF) (Molecular Probes).  We used an N-terminal-
truncated, hexahistidine-tagged expression construct of human Gαi1 with the first 
25 codons of the Gα open reading frame removed, as previously described.50  
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Point mutations were introduced using the QuickChange® site-directed 
mutagenesis protocol (Stratagene) and all vectors were verified by DNA 
sequencing.   
Protein purification 
As described in chapter II, GoLoco motif peptide was expressed either for 
4 hours at 37 ˚C or overnight at 25 ˚C with 0.5 mM IPTG in the BL21(DE3) strain 
of E. coli.  Gαi1 was expressed overnight at 25 ˚C with 1 mM IPTG in the 
BL21(DE3) strain of E. coli.  Cells were lysed using an Avestin emulsiflex and the 
resulting lysates were cleared by ultracentrifugation.  The  Gαi1 ∆N2 and RGS14-
GoLoco motif-Tenascin fusion proteins were purified using a HiTrap (Amersham 
Biosciences) column by eluting the protein with an imidazole step gradient, then 
followed by gel filtration with a Superdex-200 column (Amersham Biosciences).  
Proteins were concentrated using Vivaspin 20® centrifugal concentrators.  
Protein concentrations were determined by measuring absorbance at 280nm.  
Extinction coefficients were calculated using the method of Gill and von Hipple25. 
Fluorescence polarization binding analysis 
A thiol-reactive fluorescent probe 6-iodoacetamidofluorescein (6-IAF) 
(Molecular Probes) was conjugated to the unique cysteine on the GoLoco motif 
using the manufacture’s recommended protocol.  We do not consider any 
designs that include the addition of a cysteine to the GoLoco motif to prevent 
multiple fluorescent labeling.  GoLoco motif protein was buffer exchanged into 50 
mM Tris-Cl pH 7.5 using a PD10 desalting column, concentrated to ~50 to 100 
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uM.  Next 1 mM TCEP was added to the PD10 eluate and stirred for one hour at 
room temperature.  A 20 mM stock solution of 6-IAF suspended in dimethyl 
sulfoxide (DMSO) was diluted into the GoLoco motif protein solution to a 10-fold 
molar excess and the conjugation reaction was allowed to proceed overnight, in 
the dark at 4 °C.  Precipitate was pelleted and discarded, and 5 mM β-
mercaptoethanol (β-ME) was added to quench the reaction.  The supernatant 
containing fluorescein-GoLoco motif protein was run over a PD10 column to 
separate free probe from labeled protein.  The concentration of fluorescein-
GoLoco motif protein was quantified using UV/Vis, taking readings at 280 and 
495 nm for the protein and fluorophore respectively. The Tenascin-GoLoco 
fusion protein was used in the binding assays.   
Fluorescence polarization assays were carried out on a Jobin Yvon Horiba 
Spec FluoroLog-3 instrument (Jobin Yvon Inc.) performed in L-format with the 
excitation wavelength set at 495 nm and the emission wavelength set at 520 nm.  
Titrations were performed using a 3 x 3-mm quartz cuvette with a starting volume 
of 200 µL.  Fluorescein labeled wild type or mutant GoLoco  motif protein was 
diluted to 50 to 150 nM and the excitation and emission slit widths adjusted to 
give a fluorescence intensity >100,000 counts per second.  Wild type or mutant 
Gαi1 was added in increasing volumes from a stock solution whose initial 
concentration depended on the strength of the interaction, generally having a 
concentration of 3-10 µM.  Two to three polarization readings consisting of 3 
averaged measurements were collected for increasing concentrations of Gαi1.  
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Data was averaged and analyzed using a model for single site binding according, 
as described previously15.  
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CHAPTER IV 
PARTIAL de novo PROTEIN-PEPTIDE INTERFACE DESIGN 
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ABSTRACT 
 The ability to design a peptide de novo to bind with any desired target has 
biomedical and industrial applications ranging from vaccine development to 
biosensor design.  Taking a step towards this ultimate goal, we describe a 
method to computationally redesign the secondary structure of a component of a 
protein-peptide interface while preserving a biochemically relevant binding 
affinity.  Using the Gαi1 protein in complex with the RGS14 GoLoco motif as our 
model system, we redesigned the C-terminal portion of the GoLoco, converting it 
from a random coil to an alpha-helix, in the context of binding the wild type Gαi1 
protein.  We used the Rosetta software for the backbone and side chain 
redesign.  We used fluorescence anisotropy to experimentally evaluate the 
dissociation constants for the wild type interaction, 95 nM, and the newly 
designed interaction, 810 nM.  We then performed mutational studies on both the 
Gαi1 protein and the redesigned RGS14 GoLoco motif to confirm the location of 
binding for the redesigned GoLoco motif.      
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INTRODUCTION 
Protein-protein interactions, which govern much of the functioning of cells, 
are manipulated and utilized for both research and industrial uses.  Biosensors 
have been developed and optimized by creating or changing protein 
interactions.1; 2  Therapeutics, both small molecule and protein therapeutics, seek 
to alter protein interaction pathways.  The energetic forces that lead to protein-
protein recognition, including hydrogen bonding and hydrophobic interactions, 
have stringent geometric requirements.3; 4; 5; 6; 7; 8  Computational protein design 
seeks to model these interactions by balancing physical accuracy with speed and 
memory limitations.9  Additional geometric constraints are imposed when trying to 
redesigning a protein backbone and sequence while trying to maintain the 
proteins’ naturally occurring interactions.  The promise of computational protein 
design is to increase the scope of what we can attempt while decreasing the time 
required for development.   
 Realizing the potential for protein interface design will require improvements 
in how we model protein backbone flexibility.10  A number of approaches have 
been described to date.  Small rotations in backbone angles11 or slight 
perturbations in backbone coordinates12 have the potential to increase sequence 
search space and as well as accuracy.  A docking algorithm has been applied to 
convert a monomeric protein into a dimer.13  New backbone structures have been 
designed for helix bundles using a coiled-coil topology,14 and, in the case of a 
monomeric protein, an entirely new fold has been designed.15    
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 Here we describe a computational method that will design a distinctly 
different backbone secondary structure and compatible sequence for a portion of 
a peptide while maintaining a biochemically relevant binding affinity for one of its 
naturally occurring binding partners.  (Figure 4.1)  We use the protein design 
software, Rosetta, to build the new backbone coordinates, design new 
compatible sequences and evaluate the free energies of binding for the designs.   
Rosetta began as protein structure prediction software.16  Rosetta has made 
significant contributions toward the field of structure prediction,17 and was further 
developed to include computational protein design.18  Rosetta has been used for 
alanine scanning of protein-protein interfaces,19 altering the binding specificity of 
protein interactions,20; 21 and we have used it to predict point mutations that 
enhance protein-protein binding affinity.22  Especially relevant to the work 
presented here, Rosetta has been used for protein backbone design, including 
the redesign of a loop region of a protein,23 design of a novel monomeric 
protein15 and increasing binding affinity by lengthening peptides thereby 
increasing the buried surface area of the protein-peptide interface.24  The 
protocol we use to redesign the backbone of the C-terminal portion of a 36-amino 
acid peptide is based on methods used by the Rosetta structure prediction 
protocol.  Fragments of protein backbones taken from a non-homologous set of 
structures from the Protein Data Bank25 were combined, generating ensembles 
of redesigned protein structures.  The amino acid sequences for these new 
backbone structures were generated using the Rosetta simulated annealing 
protocol.18 
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The model system we used is the Gαi1 protein from the G-protein signaling 
system and one of its binding partners, the GoLoco motif from the RGS14 
multidomain protein.26  The RGS14 GoLoco motif interacts with both the Ras-like, 
guanine nucleotide binding domain and the all-helical domain of Gαi1.26  The C-
terminal portion of the GoLoco binds between αA and αB of the all-helical Gαi1 
domain.    We redesigned and lengthened the C-terminal portion of the GoLoco 
peptide in order to create an alpha helical backbone while maintaining the 
contacts with the Gαi1, holding the sequence of the Gαi1 protein fixed. 
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RESULTS  
The C-terminal portion of the RGS14 GoLoco motif in complex with the 
Gαi1 protein, starting from residue 519 on the Gαi1-GoLoco domain (PDB ID: 
2OM2),22 was computationally redesigned from a random coil to an alpha helix. 
(Figure 4.2)  A compatible sequence was designed for the new, redesigned 
GoLoco backbone, allowing the contacting Gαi1 side-chains and backbone to 
relax during sequence design.  Designs were selected for experimental 
characterization based on the proper location of the C-terminal GoLoco helix, the 
predicted ∆Gbinding, and the absence of the introduction of unsatisfied hydrogen 
bonding partners and high quality hydrogen bonds in the helix.   
About the Gαi1:GoLoco structure: Selection of the design site 
The RGS14 GoLoco motif spans the GTP-binding domain and the all-
helical domain of the Gαi1 protein.  The portion of the interface comprising the all-
helical domain of the Gαi1 protein and the C-terminal region of the GoLoco motif 
is thought to dictate specificity for the GoLoco-Gα protein interfaces.27  This 
segment of the interface buries approximately 660 Å2 of surface area of the 
roughly 1900 Å2 of buried surface area across the whole interface.  Members of 
the GoLoco family bind the Gαi/o proteins with affinities ranging from 4 uM to 19 
nM. 28,29  The residues in the C-terminal portions of the GoLoco motif aid in 
affinity, as shown by Adhikari et al.29  We verify the importance of this region of 
the RGS14 GoLoco motif by comparing the binding affinity of the wild-type 
interaction to that of a truncated version, with all residues following the conserved 
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DQRG motif removed, obtaining a dissociation constant of 95nM and 20 µM 
respectively.       
 
Residues just preceding the C-terminal random coil of the RGS14 GoLoco motif 
are crucial to the biochemical function of this G-protein regulatory domain.  The 
residues in the conserved set of residues act to stabilize the guanosine 
diphosphate (GDP) bound to the Gαi1 protein.  Mutational analysis done on these 
residues show them to be crucial for binding.26; 30; 31  Redesign in this area would 
likely result in the loss of binding and/or of guanine nucleotide dissociation 
inhibitor (GDI) activity for the GoLoco motif.  We therefore held this region, the 
conserved DQR triad as well as the residues immediately adjacent to it, fixed.  
The αA and αB helices in the all-helical domain of the Gαi1 protein make a groove 
where the C-terminal random coil of the GoLoco binds.  A phenylalanine at 
position 108 in the Gαi1 structure appears to occlude the groove where we wish 
to design our helix.  We sought to design the helix to bind in the groove, keeping 
in mind that the design had to include realistic chi angles for Phenylalanine 108.    
 Computational Redesign of backbone: Design of the GoLoco C-
terminal helix 
The C-terminal portion of the GoLoco motif adopts a random coil when 
bound to the all-helical domain of the Gαi1.26  Redesigning this region to be an 
alpha helix accomplishes two things; first, the secondary structure will be starkly 
different from that of the wild type, and second the coil can interact with two of 
the helices in the Gαi1 all-helical domain making a three coiled bundle.  We first 
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decided on the location to begin our design.  We selected sequence position 519 
of the GoLoco domain to begin our redesign based on the known biochemically 
crucial GoLoco region of the interface, namely the conserved three residues 
termed the conserved triad, which play a role in stabilizing the bound GDP.  We 
held these highly conserved residues fixed as well as two residues C-terminal to 
the conserved triad to protect this region of the interface.  The additional two 
residues C-terminal to the conserved triad were selected to give a buffer between 
the designed helix and the conserved triad in case altering the GoLoco backbone 
caused torsion angle movement that could propagate towards the conserved 
triad.  The challenge here was to stabilize the αB helix on the Gαi1 protein in the 
conformation seen in the Gαi1-GoLoco complex (PDB ID: 2OM2).26  Residues 83 
through 88 on the Gαi1 protein adopt a loop conformation, opening up the region 
of the binding interface with the GoLoco motif.  The same residues (numbered 
112 to 117 in PDB ID: 1ASO) adopt an alpha helical conformation in the 
GTPgammaS, unbound Gαi1 structure,32 displacing the residues by up to 5 Å and 
appearing to occlude this portion of the GoLoco binding site.  We addressed this 
structural issue by designing the new helix to start at the same height as the wild 
type random coil.   
Next we generated libraries of protein backbone fragments that would be 
used to build the C-terminal GoLoco helical backbone.  These fragments consist 
of helical backbone segments from a set of non-homologous pdb structures 
taken from the Protein Data Bank25.  The random coil region in the GoLoco motif 
was replaced by a newly designed alpha helix using Rosetta to piece together 
 121
the alpha helical pdb fragments to generate the ensembles of structures.  Each 
library contained 1000 structures.  The redesigned alpha helical regions in the 
GoLoco motif were directed to bind in the groove between αA and αB helices of 
the Gαi1 all-helical region.     
We additionally set a starting sequence for the new helical region.  The 
side-chain coordinates for all residues in the Gαi1 protein and the wild-type and 
redesigned portions of the GoLoco domain were replaced by reduced van der 
Walls spheres to aid in computational speed during the backbone design 
protocol.16  Some side chain information including the chemical character of the 
amino acids was retained in this portion of the protocol, even though the side-
chain coordinates are removed.  For example, the size of the van der Waals 
sphere changed based on the size of the all-atom side chain.  Using this side 
chain information in the centroid design mode, we set a starting sequence for the 
redesigned helix.  We set the buried residues to large hydrophobic residues to 
encourage sufficient space between the C-terminal GoLoco helix and the all-
helical region of the Gαi1.  We ran a risk of designing a protein that would either 
self-associate or form higher-order oligomers because we were designing an 
amphipathic helix in a peptide already containing an amphipathic helix in the N-
terminal region.  We believe our previous designs may have failed at least in part 
due to self-association.  (Figure 4.3 panels a through i).  The truncated GoLoco 
bound with a dissociation constant of 20 µM while the previous designs ranged 
from a Kd of greater than 57 µM to no binding detected.  We addressed the 
solubility issue by setting the starting residues for the solvent exposed region of 
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the helix to have similar charge to those of the N-terminal wild-type GoLoco helix 
so that the two helices will not be electrostatically complementary.  The final step 
in our protocol iterates for four cycles between designing the protein sequence 
for the newly designed backbone using the simulated annealing protocol,18 and 
performing gradient based minimization on the backbone and side chains.  The 
Lennard-Jones repulsion term is down-weighted for the initial cycle, and 
gradually increased through the final cycle so that Lennard-Jones repulsion 
energy does not push the two proteins apart or promote the exclusive use of 
small amino acids at the interface.   
We selected designs for experimental validation based upon several 
factors.  First, we removed from consideration any computational designs that did 
not bind in the groove between the αA and αB helices on the all-helical domain of 
Gαi1.  Second, we also did not consider designs where buried polar residues not 
participating in hydrogen bonds had been introduced, as well as poor hydrogen 
bonding in the newly designed C-terminal alpha helix.  We then ranked the 
designs based on the predicted ∆Gbinding and the quality of the hydrophobic 
packing at the binding interface.  Both the ∆Gbinding and the quality of the 
hydrophobic packing were evaluated using the interface mode of Rosetta.  
Binding energies were calculated by subtracting the calculated energy of each 
unbound protein from the calculated energy of the complex.  The predicted 
∆Gbindings vary significantly for designs selected from starting structures created 
using different amino acid initiation sequences or helix lengths.  We therefore 
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select the best designs from each run for experimental validation.  (Figure 4.3 
and Supplementary Figure 4.1). 
Experimental characterization of the redesigned GoLoco-Gαi1 
complex  
The binding affinities were experimentally evaluated using fluorescence 
anisotropy, with the fluorophor covalently attached to the GoLoco peptide on a 
unique cysteine residue pointing away from the Gαi1-GoLoco interface.  We 
obtained a dissociation constant of 95 nΜ for the wild-type GoLoco-Gαi1 complex 
and a dissociation constant of 810 nM for the redesigned GoLoco_Design11-Gαi1 
complex.  Dissociation constants have been reported for members of the GoLoco 
domain family bound to Gαi/o proteins ranging from low nano-molar, including 19 
nM for one of the four GoLoco motifs from the AGS3-C protein with GDP-bound 
Gαi1 protein29 to low micro-molar, including  2.7 to 5.6 µM for two separate 
GoLoco motifs from the GPSM2/LGN protein28.  A dissociation constant of 810 
nM falls well within a biochemically relevant range.   
We then investigated whether the newly designed C-terminal GoLoco 
helix was binding to the αA and αB helices on the Gαi1 by performing a 
mutational analysis on both the Gαi1 protein as well as the redesigned GoLoco 
motif.  We selected single and multiple mutations on the Gαi1 based on Rosetta 
∆∆Gbinding predictions indicating a loss of stability.  The mutations cover the full 
span of the αA and αB groove. (Figure 4.4)  Significant loss of binding affinity is 
seen with all of the mutations tested.  (Table 4.1 and Figure 4.5 panel a)  We 
then performed circular dichroism on the wild-type Gαi1 and the mutants to 
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ensure the mutations have not significantly destabilized the proteins.  The 
spectra for the mutants match that of the wild-type Gαi1 protein.  We selected the 
buried hydrophobic residues on the redesigned GoLoco helix and mutated each 
residue to an alanine.  Again, the mutations selected cover the entire groove 
between the αA and αB helices of the Gαi1 protein where the GoLoco helix is 
designed to bind.  The fully buried phenylalanine at position 531 results in a 
significant loss of binding affinity when mutated to an alanine.  The Tryptophan at 
sequence position 534 at the very bottom of the interface results in a modest loss 
of affinity.  The L528A, at the edge of the interface, and V524A, at the top of the 
interface, do not appear to have an effect on the binding affinity (Table 4.1 and 
Figure 4.5 panel b).  The Leucine is perhaps too solvent exposed to result in a 
significant loss.  The Valine is near a water pocket, which could decrease the 
effect from the loss of buried hydrophobic surface area.  (Figure 4.4 panel b)  We 
have not solved an x-ray crystal structure for the designed GoLoco_Design11-
Gαi1 complex to confirm that the C-terminal region of the GoLoco is forming an 
alpha helix. 
Past Designs 
The phenylalanine at position 108 of the Gαi1 protein appears to occlude 
the hydrophobic groove between αA and αB helices.  Our initial designs, shown 
in Figure 4.3, designs 1 through 9, afforded one mutation on the Gαi1, changing 
the phenylalanine to an alanine.  (Figure 4.3 panels a through i)  Mutational 
analysis of Gαi1 F108A showed a loss of binding, with the dissociation constant 
for the wild type complex at 95 nM and the F108A Gαi1 complex at 17 µM.  
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Subsequent designs kept the wild type phenylalanine at position 108.  (Figure 4.3 
panels j through l).  The designs (a) through (h) were initialized with a starting 
sequence composed of all alanines for the redesigned C-terminal GoLoco alpha 
helix.  For some of the designs the redesigned GoLoco helix was so close to the 
Gαi1 αA and αB helices that it appears larger hydrophobic amino acids were not 
accepted during the simulated annealing protocol due to an increase in the 
Lennard-Jones repulsive energy.  We altered the initial design sequence to have 
large hydrophobic amino acids at the buried positions and amino acids that are 
found both buried and solvent exposed at the peripheral interface positions.  
Solubility of the redesigned GoLoco peptide may have been another issue that 
could be addressed by the C-terminal helix initiation sequence.  In the event that 
the designed GoLoco amphipathic helices were self-associating, we introduced 
polar residues at the solvent exposed positions.   
We tried designing the C-terminal region in the absence of the N-terminal 
region of GoLoco (Figure 4.3, (d)-(g)).  Despite detecting binding using 
fluorescence polarization for two of the designs, we were unable to disrupt the 
binding with the introduction of point mutations on the Gαi1.  It is possible that the 
designed C-terminal helices were binding in the large hydrophobic groove in the 
Ras-like domain of the GDP-bound Gαi1.      
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DISCUSSION 
We designed a new backbone and sequence for the C-terminal portion of 
the RGS14-GoLoco motif, with the goal of changing the secondary structure from 
a random coil to an alpha helix.  The redesign was done in the context of the Gαi1 
binding partner.  Maintaining a nanomolar dissociation constant between a 
redesigned peptide with an altered secondary structure and an unaltered protein 
binding partner is an important step towards de novo protein-protein interface 
design.  We confirmed the location of binding for the redesigned C-terminal 
GoLoco helix using site-directed mutagenesis.  We have not confirmed the 
secondary structure of the redesigned GoLoco with x-ray crystallography.  
The goal of designing protein-protein interfaces has led to several 
successful approaches.  Huang and co-workers utilized a protocol with protein 
docking and sequence design to convert a monomeric protein to a dimer.13  Sood 
and co-workers used Rosetta to extend peptides, thereby enhancing the binding 
affinity for wild-type binding partners.24  The wild-type Gαi1 protein has numerous 
binding partners, and several crystal structures of the Gαi1 in complex with some 
of its binding partners have been solved.  The hydrophobic groove in the all-
helical domain of the Gαi1 protein that the redesigned GoLoco motif binds to is 
only known to bind members of the GoLoco motif family.  It is therefore a more 
rigorous target and highlights the success of this approach.  The computational 
protocol used in this work can be applied to any protein-protein interface and is a 
rigorous test of the computational modeling of not just side-chain movement and 
energetics but also the protein backbone.     
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Figure 4.1. Schematic of the protocol used to redesign the C-terminal helix of 
RGS14 GoLoco motif in the context of the Gαi1-GoLoco bound complex. Step (1) 
is the design of the initial backbone coordinates for the redesigned portion of the 
GoLoco motif.  Step (2) relaxes the backbone and side chain angles followed by 
a simulated annealing search for the lowest energy sequence for the given 
structure, iterating between these steps 4 times.  Step (3) involves filtering the 
output designs and ultimately selecting designs for experimental characterization.  
 
Backbone design 
Backbone and side-
chain relaxation 
Sequence design
Filter designs
4X
(1) 
(2) 
(3) 
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(a) RGS14 GoLoco motif bound to the Gαi1 protein.  
 
(b) Redesigned RGS14 GoLoco_Helix9 bound to the Gαi1 protein. 
 
Figure 4.2.  (a) The x-ray crystal structure of the RGS14 GoLoco motif bound to 
the Gαi1 protein (PDB ID 2OM2), and (b) the model of the redesigned GoLoco 
motif with the C-terminal region redesigned (shown in blue) to form a helix, 
bound to the Gαi1 protein  
 
Ras-like domain all α helical domain
Ras-like domain all α helical domain
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Figure 4.3.  Computationally modeled C-terminal GoLoco designs (a) Design 1 
through (l) Design 12. The GoLoco designs 1 through 9, panels (a) through (i), 
were designed to bind Gαi1 with a single mutation, F108A.  The GoLoco designs 
10 through 12, panels (j) through (l), were designed to bind the wild type Gαi1 
protein. 
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Figure 4.4.  (a) Residues on the Gαi1 protein at the Gαi1-GoLoco interface that 
were mutated to test for binding of the GoLoco C-terminal helix, and (b) residues 
on the GoLoco at the interface that were mutated to test for binding. 
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(a) GoLoco_helix bound to Gαi1 wild-type and mutants
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(b) Gαi1 bound to GoLoco_helix wild-type and mutants
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Figure 4.5.  Comparing binding curves for (a) the redesigned GoLoco motif 
bound to wild type Gαi1 and Gαi1 mutations designed to destabilize the complex 
and (b) Gαi1 wild type protein bound to the redesigned GoLoco motif and the 
redesigned GoLoco motif with mutations designed to destabilize the complex.  . 
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Table 4.1. Binding affinities for the Gαi1 protein bound to the redesigned GoLoc 
o motif, GoLoco_Helix951 and point mutations on the Gαi1 protein or the 
designed GoLoco helix at the redesigned interface. 
 
Mutation ∆∆GRosetta ∆∆Gexp. Kd exp.(uM) 
GoLoco_Helix951:Gαi1 — — 0.8 
    
Gαi1:I78A,A111F 0.2 >1.9 >20 
Gαi1:F95H,A101W 3.9 NBD NBD 
Gαi1:F108A 3.5 NBD NBD 
Gαi1:I78S,A111Q 0.9 NBD NBD 
    
Helix951:V524A 1.2 0.1 1.0 
Helix951:L528A 0.7 -0.1 0.7 
Helix951:F531A 3.2 >1.9 >20 
Helix951:W534A 4.1 0.2 1.1 
    
NBD - no binding detected   
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  Wild type  DIECLVELLNRVQSSGAHDQRGLLRKEDLVLPEFLQ------------ 36 
 Design 1   DIECLVELLNRVQSSGAHDQRSPRMEDAAKDALRALQIWENVR----- 43 
 Design 2   DIECLVELLNRVQSSGAHDQRSPDLQELLDAIKKMLEALKKHF----- 43 
 Design 3   DIECLVELLNRVQSSGAHDQRDAQRREIIRFALEAIEELDKMF----- 43 
 Design 4   ----------------------NEQLKKELWEAIEWFLRQF------- 19 
 Design 5   ----------------------DEDYREDLRRMVEWHEKQW------- 19 
 Design 6   ----------------------LDDWKDDLEEVVERVLRRR------- 19 
 Design 7   ----------------------FEQLRKELKEACEWHERQR------- 19 
 Design 8   DIECLVELLNRMQSSGAHDQRGPKTERRIKLAIDAIKGAEIAERLMRQ 48 
 Design 9   DIECLVELLNRVQSSGAHDQRGIELQRWLQLAQDVFKALIWLF----- 43 
 Design 10  DIECLVELLNRVQSSGAHDQRSLLRQEEMQRAIRDFAKWF-------- 40 
 Design 11  DIECLVELLNRVQSSGAHDQRGLSEWQRFWRRWLEWLIYLF------- 41 
 Design 12  DIECLVELLNRVQSSGAHDQRGLLSNEEVFRALRDFDRWF-------- 40 
 
Supplementary Figure 4.1.  Amino acid sequences of the wild type RGS14 
GoLoco aligned with Designs 1 through 12.  Designs 4 through 7 were designed 
with just the C-terminal portion of the GoLoco motif.  The unique Cystine residue 
located at sequence position 4 is a Glycine in the wild type GoLoco motif.  The 
fluorophor is attached to this residue. 
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METHODS 
Rosetta  
All energy calculations and side chain and backbone relaxation 
simulations were performed with the molecular modeling program Rosetta32.   
We used the following command lines to run the backbone modeling protocol, 
called loop modeling in the Rosetta code: 
 
For the centroid-mode backbone design we first created a fasta file for the 
GoLoco-Gαi1 complex.  We altered the sequence for the C-terminal region of the 
GoLoco that was to be redesigned, extending the sequence to allow for the 
conversion from a random coil to an alpha helix.  We then altered the pdb file by, 
removing the atomic coordinates for the C-terminal region of the GoLoco that 
was to be redesigned, replacing the coordinates with zeros.  We also added 
residues, extending the C-terminal region.  The sequence in the fasta file had to 
match the sequence in the altered pdb file.  We generated a set of alpha helical 
backbone fragments from a non-homologous set of pdb files from the Protein 
Data Bank.   
 
rosetta.gcc aa g000 _ -s g000.pdb –loops –cst cst  
 
where the fasta file is named g000_.fasta, the pdb file is named g000.pdb, the 
fragment files are named aag000_03_04.200_v1_3 and 
aag000_09_04.200_v1_3.  The –cst cst command can be used for a constraint 
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file, containing constraints designed to direct the location of binding for the 
redesigned C-terminal helix.  We did not use constraint files for the majority of 
the designs here, including the redesigned GoLoco discussed in the results 
section.   
The resulting ensemble of designed structure are missing the coordinates for the 
side chain atoms.   The original pdb file was then merged with the designed 
structures so that the side chain coordinates for all wild type residues could be 
recovered and not modeled.  The redesigned sequence positions and 
neighboring sequence positions were relaxed using the Rosetta simulated 
annealing protocol, with the following command line: 
 
rosetta.gcc –design –l list_of_pdb_structures –tail  -begin 343 –end 368 –chain _ 
-series bb –protein g000 –resfile tail.resfile –ex1 –ex2 –extrachi_cutoff 1 
 
where list_of_pdb_structure is a file containing the name of the pdb files 
generated using the centroid design mode and merged with the original pdb file.  
–begin 343 and –end 368 indicate the start and end of the region to be 
redesigned.  The sequence positions here do not match those from the original 
pdb file because Rosetta renumbers all sequence positions, starting with 1 and 
continuing sequentially through both protein chains. 
Construction and cloning of protein designs  
The DNA sequence for the GoLoco motif of RGS14 (residues 496-531) 
was cloned into pET21b as a C-terminal fusion to the small protein Tenascin.  
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Tenascin was included to aid in the expression and purification of the peptide.  
The sequence for a hexahistidine tag was placed at the C-terminus of the 
construct.  Residue G498 of the wild type GoLoco motif was mutated to a 
cysteine to enable the covalent labeling of the thiol-reactive fluorescent probe 6-
iodoacetamidofluorescein (6-IAF) (Molecular Probes).  We used an N-terminal-
truncated, hexahistidine-tagged expression construct of human Gαi1 with the first 
25 codons of the Gα open reading frame removed, as previously described.50  
Point mutations were introduced using the QuickChange® site-directed 
mutagenesis protocol (Stratagene) and all vectors were verified by DNA 
sequencing.   
Site-directed mutagenesis was used to remove a Sac1 cut site from the 
pET21b vector, leaving a unique Sac1 cut site in the GoLoco gene.  The C-
terminal portion of the GoLoco was removed by incubating the DNA at 37° C for 
1 hour with Sac1 and Xho1 with the addition of BSA.  The linearized plasmid was 
purified using gel electrophoresis and then the Qiagen gel extraction kit.  Oligos 
for the designs 1 through 7 were ordered from Lineberger Tissue Culture Facility.  
The oligoes were annealed and ligated into the plasmid over night at 4° C.       
Protein purification 
As described in chapter 1, GoLoco motif peptide was expressed either for 
4 hours at 37 ˚C or overnight at 25 ˚C with 0.5 mM IPTG in the BL21(DE3) strain 
of E. coli.  Gαi1 was expressed overnight at 25 ˚C with 1 mM IPTG in the 
BL21(DE3) strain of E. coli.  Cells were lysed using an Avestin emulsiflex and the 
resulting lysates were cleared by ultracentrifugation.  The  Gαi1 ∆N2 and RGS14-
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GoLoco motif-Tenascin fusion proteins were purified using a HiTrap (Amersham 
Biosciences) column by eluting the protein with an imidazole step gradient, then 
followed by gel filtration with a Superdex-200 column (Amersham Biosciences).  
Proteins were concentrated using Vivaspin 20® centrifugal concentrators.  
Protein concentrations were determined by measuring absorbance at 280nm.  
Extinction coefficients were calculated using the method of Gill and von Hipple88. 
Fluorescence polarization binding analysis 
A thiol-reactive fluorescent probe 6-iodoacetamidofluorescein (6-IAF) 
(Molecular Probes) was conjugated to the unique cysteine on the GoLoco motif 
using the manufacture’s recommended protocol.  We do not consider any 
designs that include the addition of a cysteine to the GoLoco motif to prevent 
multiple fluorescent labeling.  GoLoco motif protein was buffer exchanged into 50 
mM Tris-Cl pH 7.5 using a PD10 desalting column, concentrated to ~50 to 100 
uM.  Next 1 mM TCEP was added to the PD10 eluate and stirred for one hour at 
room temperature.  A 20 mM stock solution of 6-IAF suspended in dimethyl 
sulfoxide (DMSO) was diluted into the GoLoco motif protein solution to a 10-fold 
molar excess and the conjugation reaction was allowed to proceed overnight, in 
the dark at 4 °C.  Precipitate was pelleted and discarded, and 5 mM β-
mercaptoethanol (β-ME) was added to quench the reaction.  The supernatant 
containing fluorescein-GoLoco motif protein was run over a PD10 column to 
separate free probe from labeled protein.  The concentration of fluorescein-
GoLoco motif protein was quantified using UV/Vis, taking readings at 280 and 
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495 nm for the protein and fluorophore respectively. The Tenascin-GoLoco 
fusion protein was used in the binding assays.   
Fluorescence polarization assays were carried out on a Jobin Yvon Horiba 
Spec FluoroLog-3 instrument (Jobin Yvon Inc.) performed in L-format with the 
excitation wavelength set at 495 nm and the emission wavelength set at 520 nm.  
Titrations were performed using a 3 x 3-mm quartz cuvette with a starting volume 
of 200 µL.  Fluorescein labeled wild type or mutant GoLoco  motif protein was 
diluted to 50 to 150 nM and the excitation and emission slit widths adjusted to 
give a fluorescence intensity >100,000 counts per second.  Wild type or mutant 
Gαi1 was added in increasing volumes from a stock solution whose initial 
concentration depended on the strength of the interaction, generally having a 
concentration of 3-10 µM.  Two to three polarization readings consisting of 3 
averaged measurements were collected for increasing concentrations of Gαi1.  
Data was averaged and analyzed using a model for single site binding according, 
as described previously26.  
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 We developed a protocol to predict point mutations to enhance protein-
protein binding affinity, evaluated a protocol to redesign protein-peptide binding 
specificity and developed a protocol to redesign the backbone and sequence of a 
peptide in the context of a wild type binding partner.  We used the protein design 
software, Rosetta, for these three applications.  The model system that we used 
to validate these protocol is the Gαi1 protein from the heterotrimeric G-protein 
complex bound to the GoLoco regulatory domain from RGS14.  We also use the 
E2-E3 complex, E6AP bound to UbcH7 for the protocol to predict affinity 
enhancing point mutations.  We found that our protocol to model single point 
mutations that will increase buried hydrophobic surface area is an efficient and 
reliable way to enhance protein-protein binding affinity.  This protocol required 
modeling of the fewest degrees of freedom and relied on our ability to model the 
hydrophobic effect, which we understand and can model well.  Rosetta’s energy 
function exhibited good predictive power in this context.   
We then evaluated an automated protocol to redesign protein-peptide 
binding specificity.  This application requires the protocol to select sequences to 
stabilize desired protein-peptide interactions while destabilizing undesired 
interactions and thus is a more stringent evaluation of our protein design 
protocol.  The goal was to design an orthogonal binding interface, with a 
redesigned protein-peptide complex that has a binding affinity similar to that of 
the wild type complex but that will not interact with the wild type protein 
components.  We did have some success using this protocol.  Four designs 
passed our set of filters, and two of the four designs have the intended binding 
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specificity.  The redesigned specificity for these two designs is more modest than 
desired, however.  Perhaps more importantly is the fact that our protocol 
generated more than 1500 designs, yet only four passed our set of filters.  We 
relaxed our filters and selected additional designs, but none were able to recover 
wild type binding affinity.  It is possible that fixing the backbone torsion angles to 
those found in the x-ray crystal structure limited the sequence space that this 
protocol was able to search.  Expanding this protocol to include flexibility in the 
backbone torsion angles could improve the quality of the designed hydrogen 
bonds or redesigned hydrophobic cores.  This could increase the number of 
designs generated that pass our initial set of filters.   
Lastly, we examined our ability to design a new peptide backbone in the 
context of a wild type binding partner.  Our approach redesigned the C-terminal 
region of the 36-amino acid GoLoco domain, allowing the N-terminal region to 
direct binding to the wild type partner, Gαi1.  We sought to change the secondary 
structure of the GoLoco C-terminal region from a random coil to an alpha helix.  
We confirmed that the new C-terminal GoLoco helix does bind the Gαi1 as 
designed using site-directed mutagenesis.  Solving the crystal structure of the 
redesigned interface is desired to determine how close the redesigned GoLoco- 
Gαi1 complex is to the computationally generated structure.  Ultimately the goal is 
to design a peptide or protein in the context of a binding partner without relying 
on an initial wild type region to direct and enhance binding.  Further evaluation of 
the redesigned GoLoco by comparison with an experimentally determined 
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structure is needed to determine how successful this protocol is with this more 
conservative design approach.  
  
 
